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Post-traumatic seizures (PTS) are heterogeneous and their development has been 
proposed to depend on variation in the type and severity of injuries and differing genetic 
backgrounds of the patients. Identification of patients at risk for developing PTS has significant 
public health implications as those who suffer from PTS have limitations of daily living such as 
driving and may have increased caretaker burden and difficulty with reemployment.  
Genetic studies have revealed that several nuclear genetic variants may act as risk factors 
in the development of PTS. Many mitochondrial diseases due to variations in mitochondrial 
DNA (mtDNA) have seizure as part of their phenotype.  However, no studies have yet focused 
on the role that mtDNA may play in the development of PTS.   
The goals of this study are to explore roles that mtDNA variants may play as independent 
risk factors for the development of both early (EPTS) and late (LPTS) post-traumatic seizures.  
To explore whether mtDNA variants act as effect modifiers of other injury related factors  in 
relation to the development of EPTS/LPTS, and to explore if mtDNA variants effect the 
relationship between  LPTS and GOS measures at 6 months post-injury. 
Nineteen mtDNA variants were genotyped in a population of 136 severe TBI patients. 
Additional genotypes were collected for 6 of the variants in the second stage of the analysis 
(n=332).  No variant was significantly associated (at p<0.05) in the univariate analysis with 
EPTS or LPTS in either the smaller or larger subsets of the population. The A8701G variant 
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showed the strongest association with EPTS in the univariate analysis (p=0.084) and was entered 
into a multivariate model. This model showed a significant effect for the variant (p=0.041). 
T16519C had the strongest univariate association with LPTS (p=0.053) and retained borderline 
significance when entered into a multivariate model (p=0.095).  T16519C appeared to have the 
strongest trend towards a potential modifying effect with SDH and cranial surgery on the 
outcome of LPTS.  T16519C and T195C may also have possible trends towards lower functional 
outcomes in those with LPTS. 
While no significant independent associations were found between the 19 mitochondrial 
variants and the outcome of PTS, the findings from this study may help guide future research in 
this area.  This study was able to provide limited evidence that mitochondrial polymorphisms 
may in fact play a role in unraveling the complex phenotype of PTS. 
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1.0  INTRODUCTION  
Traumatic brain injury (TBI) is one of the leading causes of death and disability in the 
United States, and its effects are felt across all demographic boundaries.[1] Approximately 1.7 
million people in the United States sustain a traumatic brain injury (TBI) each year accounting 
for 1.4 million emergency department visits and 275,000 hospital admissions. [2]  Current 
estimates suggest that between 3.2-5.3 million Americans live with the sequelae associated with 
TBI that include; reduced quality of life, and loss of one or more physical and mental 
functions[3].  Furthermore, more than $60 billion is spent yearly to cover health expenses, 
disability and lost wages due to TBI [4]. These personal, public health and financial impacts 
warrant further investigation of the potential physiologic and genetic risk factors related to the 
identification, prevention, and treatment of TBI and its related sequelae. 
Post-traumatic seizures (PTS) are a serious complication after TBI. They can occur soon 
after injury as a consequence of acute pathophysiological changes due to the neurological insult, 
or they may develop months to years after the initial injury [5]. TBI accounts for as much as 20% 
of all symptomatic cases of epilepsy in the general population [6].  Those with TBI are twelve 
times more likely than a person in the general population to suffer seizures [7].  Up to 80% of 
PTS occur within the first 24 months of injury [8]. Recurrence is also a major concern as up to 
86% of those who have one seizure after TBI will have another within two years [5]. The 
likelihood of developing PTS increases with injury severity as more than 15% of those with 
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severe TBI develop seizures, a risk factor that remains elevated for many years post injury [9]. 
PTS also has significant implications for future treatment and quality of life of the TBI patient, 
including loss of independence, mobility, and employment opportunities [5]. Anticonvulsant 
medications are often given prophylactically to PTS patients to prevent further secondary brain 
injury and possibly aid in improving their functional outcomes [5].  However, anticonvulsant 
medications used to treat PTS can produce unwanted side effects, including further 
neurobehavioral impairment, and sedation [10].  While many of the drugs studied to prevent PTS 
have shown some effectiveness at decreasing early seizures, they have not shown any real 
success in preventing late seizures or the development of post-traumatic epilepsy as they 
primarily suppress seizure activity [11]. Early seizures may be more of a direct reaction to brain 
damage, while late seizures may be due to damage of the cortex by free radicals generated 
following iron deposition in brain from some form of intracranial hematoma[12]. Temkin 
suggests that further work needs to be done to understand the underlying mechanisms of PTS in 
order to develop therapies that could identify targets for slowing, stopping and more effectively 
treating seizures.  
The search to uncover these underlying mechanisms in PTS has led to studies that have 
explored genetic links to certain seizure disorders [13-15], and to studies that have explored how 
nuclear genetic variability affects the development of PTS [16-20]. In addition to potential 
nuclear genetic variants having an impact on seizure development, it is also known that many 
inherited mitochondrial diseases include seizure as part of their pathogenesis [21, 22].  It has 
been estimated that as many as 40-50% of patients with mitochondrial encephalopathy suffer 
from seizures [23], and specific mitochondrial mutations are associated with some forms of 
myoclonic epilepsy [23]. For example, Myoclonic Epilepsy with Ragged Red Fibers (MERRF) 
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involves several polymorphisms in mtDNA, with clinical hallmarks that include progressive 
epilepsy and a distinct appearance of mitochondria in muscle fibers [24]. Mitochondrial 
Myopathy, Encephalopathy, Lactic Acidosis and Stroke (MELAS) syndrome can be caused by 
multiple mtDNA mutations and has clinical features that include seizures, hemiparesis, 
hemianopia, and blindness among others [25].  From the publication of the complete 
mitochondrial genome in 1981 [26], over 200 pathogenic point mutations and larger 
rearrangements (i.e. substitutions, deletions) have been associated with disease [27]. 
To date there has been scant mention in the literature investigating the relationship 
between TBI and mtDNA variations (polymorphisms). The few articles pertaining to the topic 
have focused primarily on deletions of the mitochondrial genome as a consequence of acute 
brain injury [28, 29].  McDonald reported that a deletion at mtDNA base pair 7346 was less 
frequent in long term survivors of TBI and hypothesized that since the survivors lacked the 
deletion, they were able to better cope with the injury compared to those who died of similar 
injury.  Lifshitz investigated whether specific mtDNA deletions would be seen as a consequence 
of TBI due to altered metabolic states and oxidative stresses incurred during the injury. He did 
not find any association between TBI and mtDNA deletions, but did find that mitochondrial 
protein yields from the injured brains were lower than those of uninjured controls. 
Despite the paucity of published papers looking at mtDNA and TBI and the complete 
lack of literature regarding mtDNA and PTS, at least one other study has explored specific 
mtDNA variants as predictors of mortality [30]. Canter and colleagues sought to determine 
whether specific genetic variations in mtDNA known to impact energy production were 
associated with the risk of in-hospital mortality after severe trauma as assessed by Injury 
Severity Scores (ISS). They selected three mtDNA polymorphisms at positions 4216, 10398, and 
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4917 because variants at these positions are known to alter the amino acid sequence of key 
subunits of the Complex I enzyme of the respiratory chain. They demonstrated that one mtDNA 
variant (the 4216 T allele) was an independent predictor of increased mortality in the 
multivariate model [30].  Furthermore, the findings that seizure activity is an important sign in 
the early presentation of several mitochondrial encephalopathies implies that preexisting variants 
in mtDNA might predispose one to developing seizures after traumatic brain injury.  
1.1 RATIONALE 
Traumatic brain injury (TBI) represents a major public health issue with some 1.7 million 
people sustaining TBI, 275,000 requiring hospitalization and more than 50,000 deaths attributed 
to it annually in the United States [1]. Up to $60 billion is spent yearly to cover health expenses 
and lost wages due to TBI [31], and 3.2-5.3 million people suffer from the long term sequelae of 
TBI that include reduced quality of life, and the loss of one or more physical or mental functions 
[3]. One common and potentially debilitating consequence of TBI are post-traumatic seizures 
(PTS), which are seizures that occur after head injury and thought to be causally related to the 
trauma itself [32]. Post-traumatic seizures are typically defined as early (provoked) when they 
occur within the first seven days of injury or as late (unprovoked) if they occur after 7 days [33].  
Post-traumatic epilepsy (PTE) is defined by two or more late seizures after TBI [34].  The 
probability of developing PTS or PTE is significantly correlated with type (closed versus 
penetrating) and severity of TBI (mild, moderate and severe). The prevalence of PTS ranges 
from as high as 53% in military populations with penetrating TBI [35], to approximately 10-15% 
among civilians with severe TBI [9].  
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PTS is a heterogeneous condition and it has been proposed to depend on variation in the 
type, location, severity, number of injuries, secondary brain insults, as well as on the different 
genetic backgrounds, ages and genders of the patients [36, 37].  Injury severity is by far the best 
predictor of who will go on to develop PTS [32, 38]. However, animal models of TBI that use a 
fluid percussion technique to simulate moderate to severe closed head injury have also 
demonstrated that certain regions of the cerebrum (e.g. the frontal neocortex and temporal lobes) 
are more likely display seizure activity [39-42]. Lesion type and lesion location have also been 
associated with the development of PTS in several human studies [38, 43-45].  
PTS may also play a role in moderating functional outcomes after TBI.  PTS has been 
associated with poorer GOS scores and higher incidence of behavioral abnormality in patients 
with severe TBI in India [46].  Late PTS has also been associated with a higher incidence of 
depression [47]. A 5 year follow-up study of rehabilitation and reemployment in Finland showed 
that late PTS was associated with poorer functional and social outcomes and was a considerable 
factor in hospital readmission [48]. Overall, it appears that PTS can result in greater psychiatric 
problems as well as reduced general health and poorer functional and social outcomes [12].  
Studies exploring genetic susceptibility to seizure disorders have expanded significantly the 
number of potential candidate genes involved with seizures [14, 15, 49], while others have begun 
to expand the concept of genetic susceptibility to TBI outcomes [50, 51]. Only recently have 
genetic studies revealed that several nuclear genetic variants (APOE, A1AR, GAD) may act as 
risk factors in the development of PTS [16-20]. While no studies have yet to focus on the role of 
mitochondrial DNA in the development of PTS, strong evidence has emerged that variations in 
the mitochondrial genome are linked to mitochondrial encephalopathies that have disrupted 
cellular metabolism and seizure as part of their phenotype [52-54]. 
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1.2 SPECIFIC AIMS 
The goals of this proposed project are to use data from our current cohort of severe TBI 
patients to explore roles that mtDNA variants may play as independent risk factors for the 
development of both early PTS (EPTS) and late PTS (LPTS) (Aim 1). To explore whether 
mtDNA variants act as effect modifiers of other injury related factors (mechanism, lesion type) 
in relation to the development of EPTS or LPTS (Aim 2), and to explore if mtDNA variants 
affect the relationship between LPTS and functional outcome measures (GOS) at 6 months post-
injury (Aim 3). 
 
Specific Aim 1: Examine the contribution of mtDNA variation to the development of both EPTS 
and LPTS in this cohort of severe TBI patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mtDNA 
Variants 
 
PTS 
EPTS 
LPTS 
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Specific Aim 2:  Examine if selected injury factors associated with increased risk of both EPTS 
and LPTS, are affected by the presence of specific mtDNA variants in this cohort of severe TBI 
patients. 
 
 
 
 
 
 
Specific Aim 3: To examine if EPTS and LPTS are associated with functional outcomes and if 
this relationship is affected by mtDNA variants in this population of severe TBI patients. 
 
 
 
 
 
 
 
These data present a unique opportunity to test hypotheses that mtDNA variants can help 
explain the variability of PTS in severe TBI patients either as independently acting risk factors or 
as interacting variables in regards to other injury related factors such as location or lesion type 
that are thought to affect the development of PTS. Furthermore, the combined effects of mtDNA 
variants and other injury characteristics may influence functional and social outcomes after 
PTS 
EPTS 
LPTS 
 
 
Injury Factors 
 
mtDNA 
Variants 
 
PTS 
EPTS 
LPTS 
 
 
Functional Outcome 
GOS 
 
 
mtDNA 
Variants 
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severe TBI. Knowledge of the contribution of mtDNA variants may lead to changes in how anti-
convulsive drugs are administered in the acute and long-term phases of TBI recovery. A better 
understanding of the injury factors may aid in the design of future injury prevention studies. The 
effects of mtDNA variation coupled with injury characteristics may serve as predictors of long 
term outcome after injury. 
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2.0  LITERATURE REVIEW 
2.1 TRAUMATIC BRAIN INJURY 
2.1.1 Definition 
The impact of traumatic brain injury (TBI) on the population has been recognized as a 
national public health issue that requires a response from the public health community to prevent 
and understand their long-term consequences [55].  In response to a Federal Interagency Head 
Injury Task Force Report, the National Center for Injury Prevention and Control (NCIPC) of the 
CDC began developing surveillance systems to study TBI at the population based level [55]. In 
1995, the CDC published the standard clinical case definition of TBI as an occurrence of injury 
to the head (arising from blunt or penetrating trauma or from acceleration-deceleration forces) 
that is associated with symptoms or signs attributable to the injury including: decreased level of 
consciousness, amnesia, other neurological or neuropsychological abnormalities, skull fracture, 
diagnosed intracranial lesions or death as well as the case definition for data systems using ICD 9 
codes [56].  The NCIPC also defined a four-step public health model for studying TBI in which 
each step occurs simultaneously and informs the others. The first step is to create surveillance 
systems to collect basic information regarding TBI events. The second is to identify factors that 
increase the risk of TBI or are protective.  The third step is to design and test interventions. And 
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the final step is the implementation of successful strategies and the continued use of surveillance 
to evaluate their impact at the national level [57].  This ongoing system has led to a more 
accurate understanding of the impact that TBI has on the population in both physical and 
economic terms. 
 
2.1.2 Impact and Burden 
TBI’s can result in loss of the ability to work or perform daily activities, and are often 
associated with the need for increased hospitalization or long-term care[58]. TBI is also a known 
comorbidity for other health adverse conditions including binge drinking [59], depression [60], 
Alzheimer’s and dementia development [61], and overall increased mortality [62]. Failure to 
recognize the signs and symptoms of TBI can result in under diagnosis and become yet another 
barrier to obtaining appropriate services that adds to the overall personal and economic burden 
[58].  Injuries in general exact an enormous burden on the health care system of the United States 
as over 50 million medically treated injuries per year have resulted in a total lifetime cost of over 
400 billion dollars in medical treatment and lost productivity [31]. It is estimated that of the total 
expenditures, between $50-60 billion is spent yearly to cover health expenses, disability and lost 
wages due to TBI [4, 55].  TBI has a tremendous impact on both the civilian and military 
populations as one of the leading causes of death and disability. 
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2.1.3 TBI Epidemiology in Civilians 
TBI is one of the leading causes of death and disability in the United States, and its 
impacts are felt across all demographic strata.  Approximately 1.7 million civilians in the United 
States sustain a TBI each year accounting for 1.4 million emergency department visits, 275,000 
hospital admissions and approximately 53,000 deaths, which accounts for over 30% of all injury 
related deaths in the civilian populations of the US[2]. The majority of TBI related deaths are 
caused by falls, motor vehicle accidents and firearms. Children 0-14, adolescents 15-19 and 
adults older than 65 are the most likely to sustain a TBI, and in the youngest and oldest strata 
falls accounted for a third of all TBI related injuries [1]. Overall, males are 1.4 times more likely 
to suffer a TBI than females [2].  There is also evidence that African Americans have a higher 
overall risk of TBI compared to whites or other minorities, and recent analyses by Faul and 
colleagues found that African Americans have an overall incidence rate of Emergency 
Department visits of 568.7 compared to 456.6 for whites and 345.2 for American Indians, 
Alaskan Natives, or Pacific Islanders [2]. Other work has shown that African Americans were 
2.76 times more likely to be nonproductive than whites one year after TBI [63].  
Current prevalence estimates place the number of American civilians living with the 
long-term effects and disabilities of TBI at between 3.17-3.32 million. This number may actually 
be an underestimate as it only includes hospitalizations for TBI and doesn’t account for those 
who were treated and released by emergency departments or those who never sought treatment 
[3]. Other work has shown that approximately 200,000 TBIs are treated yearly in outpatient 
settings or doctor’s offices [4].  
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2.1.4 TBI in Military Populations 
 As substantial as the TBI numbers are in the civilian populace, they do not include 
injuries sustained by military personnel during the wars in Afghanistan and Iraq.  TBI has been 
called the “signature wound” of U.S. troops because it appears to account for a larger proportion 
of casualties than it has in other recent wars [64].  Advances in protective body armor and 
helmets have reduced the incidence of penetrating head injuries and death, but closed head TBIs 
continue to occur.  Since the beginning of these two wars, over 1.6 million personnel have served 
in the theater and estimates of TBI among wounded soldiers has been estimated to be as high as 
22% [64]. In a sample of 433 individuals with TBI who were treated at Walter Reed Medical 
Center, 56% had moderate to severe head trauma, and 88% of all TBI patients sustained closed 
head injuries confirming that closed head injuries have become more common in these conflicts 
than in the past. [65].  Blast injury is a significant factor in many of these injuries due to the 
widespread use of improvised explosive devices [66].  Military sources report that nearly two-
thirds of army war zone evacuations are due to blast injury [65].  One recent analysis of TBI 
hospitalizations of US Army soldiers deployed in Afghanistan and Iraq between 2001 and 2007 
identified 2898 inpatient episodes of TBI.  46% of injuries were classified as Type I (most 
severe), 54% were Type II (mild to moderate), and <1% were Type III (most mild).  The overall 
admission rates for TBI were 24.6 for Afghanistan and 41.8 for Iraq per 10,000 soldier years.  
Over time, hospitalization rates for TBI rose for both campaigns as well [67]. 
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2.1.5 TBI Classification and Severity 
There are different systems of classifying TBI: clinical indices of severity; pathoanatomic 
indices for describing injury type; and physical mechanisms for describing causative forces of 
injury.  Pathophysiological, and injury cascade markers have also been incorporated as additional 
measures of TBI severity [68].  
The most widely used tool for classifying TBI patients is the Glasgow Coma Score 
(GCS) that was developed by Teasdale and Jennett in 1974. This scale provides an effective way 
for clinicians to determine the depth and duration of impaired consciousness after TBI by 
measuring three independent components of behavior:  eye opening, motor responsiveness, and 
verbal performance (see Figure 1) [69]. The scale runs from 3 (comatose and nonresponsive) to 
15 (no deficits in any of the three domains).  Once the patient is stabilized, the test is 
administered and the scores for each domain are summed to create the composite score. The 
GCS scale is the most commonly used neurological injury scale for adults due to its high intra-
observer reliability and good predicative capabilities [70].  Many studies have classified Severe 
TBI from 3-8, Moderate 9-12 and Mild from 13-15 [71, 72].  There have been other variations 
used as well within and outside the U.S. [73].  While the extreme ends of the scale are relatively 
easy to interpret, scores in the middle are more subjective and may lead to potential 
misclassification.    
The Defense and Veterans Brain Injury Center uses a modification of the GCS scale to 
determine the severity of TBI in those serving in the military (see Figure 2). Mild TBI is often 
referred to as concussion and may or may not involve a brief loss of consciousness (LOC) of <1 
hour or an episode of post-traumatic amnesia (PTA) of <24 hours and a Glasgow Coma Score 
(GCS) between 13-15.  Moderate TBI typically has LOC of >1 hour, but <24 hours, PTA lasting 
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from 24hours to 7days and a GCS between 9-12.  Severe TBI is typically defined as LOC for 
>24 hours, PTA lasting more than 7 days, and a GCS <8. (from 
http://www.traumaticbraininjuryatoz.org/Home.aspx) 
 
 Glasgow Coma Score   
Eye Opening (E) Verbal Response (V) Motor Response (M) 
4 – Spontaneous Eye opening 
3 – Eyes Open to Speech 
2 – Eyes Open to Pain 
1 – No Eye Opening 
 
5 – Alert and Oriented 
4 – Confused, yet coherent 
3 – Inappropriate words and jumbled    
      phrases of words 
2 – Incomprehensible sounds 
1 – No Sounds 
 
6 – Obeys commands fully 
5 – Localizes to noxious stimuli 
4 – Withdraws from noxious stimuli 
3 – Abnormal flexion 
2 – Abnormal extension 
1 – No response 
Figure 1: Glasgow Coma Score 
Adapted from Teasdale and Jennet, 1974 [69] 
 
GCS as used by DVBIC 
Severity Glasgow Coma Scale  
(total) 
Loss of Consciousness 
(duration) 
Post-Traumatic Amnesia 
(duration) 
Mild 13-15 < 1 hr. < 24 hrs. 
Moderate 9-12 1-24 hrs. 24 hrs. to < 7 days 
Severe 3-8 > 24 hrs. 7 days or more 
Figure 2 TBI Severity as used by Defense and Veterans Brain Injury Center 
Adapted from Helmick et al. [74] 
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2.1.6 Complications Related to TBI 
The complications of TBI vary with severity of injury, with moderate and severe patients 
experiencing much greater dysfunction than those diagnosed with mild TBI. Approximately 80% 
of patients presenting to Emergency Departments are classified as mild (GCS 13-15), 10% are 
moderate (GCS 9-12) and 10% severe (GCS <8) [75]. 
Presenting clinical symptoms of mild TBI include headache, nausea and vomiting, but 
may also include disorientation, confusion and/or amnesia.  Patients with moderate TBI have a 
widely varied immediate clinical presentation that can include LOC, post-traumatic seizures 
(PTS), confusion and some amnesia, but they can typically still follow commands.  Severe 
patients present with a GCS <8, and are often unconscious and nonresponsive [76].  
Mortality is an important consideration in TBI studies, of the 1.7 million TBI’s that occur 
each year in the United States, 3.0% (53,000) result in death [2]. The risk of mortality increases 
with the severity of injury and can act as confounder when trying to investigate other outcomes 
related to TBI. 
TBI is a heterogeneous condition that can have both immediate and longer-term 
complications associated with it. The risk of immediate complications increases with severity of 
injury and can include: immediate seizures, hydrocephalus (post-traumatic ventricular 
enlargement), CSF leaks, infections, cranial nerve injuries, organ system failure and multi-organ 
trauma [77]. Long-term complications or outcomes are typically those that persist for more than 
6 months after injury and can include:  changes in neurocognition, neurologic deficits, 
psychiatric disorders and social impacts [73].  Although the morbidity associated with TBI is 
highly variable, this review will focus on one common and serious complication, Post-Traumatic 
Seizures (PTS). 
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 PTS is a major neurologic outcome after TBI. The review committee of Gulf War and 
Health: Volume 7: Long-term Consequences of Traumatic Brain Injury evaluated a total of 29 
studies regarding the association between TBI and the development of seizures.  Across those 
studies the risk of seizures after severe TBI was 17-95 times higher than the uninjured 
population, and 2.9-6.6 times higher in those with moderate TBI.  In the studies of mild TBI, the 
risk of seizure was 1.5 times higher than in the uninjured population.  The committee concluded 
that there was sufficient evidence of an association between both severe and moderate TBI and 
the development of seizures after injury, but concluded that there was limited evidence of an 
association between mild TBI and development of seizures ([73] see Chapter 7, pp. 197-209). 
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2.2 POST-TRAUMATIC SEIZURES 
2.2.1 Definitions 
 The association between head injuries and the development of seizures has been 
recognized for thousands of years. References of seizures developing in patients surviving severe 
head injury date back as far as 3000 B.C. [78].  According to Caveness, “the relation of 
craniocerebral trauma to convulsive seizures was recognized by Hippocrates (460-357BC) in his 
treatise “Injuries of the Head” [79].  The terms post-traumatic seizure (PTS) and post-traumatic 
epilepsy (PTE) are often used to describe the same thing: seizures occurring after head trauma 
that are thought to be causally related to the trauma itself [32]. In some settings, the diagnosis of 
epilepsy has been reserved for patients who have had two or more unprovoked seizures [6]. PTE 
is typically defined as recurrent, late seizures that occur more than one week after injury [80].  
As Frey points out there are disadvantages of waiting for a second seizure to occur before 
applying the term PTE.  She notes that some patients will be excluded because of the long period 
between the initial seizure and the second seizure. Others may not have their first seizure until 
long after the injury has occurred, and the practice of using antiepileptic drugs after a first 
seizure may alter the course of seizure development [32]. While there is still debate as to what 
differentiates late occurring PTS and PTE, the term late post-traumatic seizure (LPTS) will be 
used throughout this literature review when referring to seizures that occur later than 1 week 
after injury 
 18 
2.2.2 Early and Late PTS 
 Jennett was one of the first authors to divide seizures occurring after TBI into early PTS 
(EPTS) and late PTS categories (LPTS). He defined early seizures as those occurring between 1-
7 days after injury and late as those occurring beyond 7 days [33].  It is also common in the 
literature for early seizures to be referred to as provoked, whereas late seizures are termed 
unprovoked [34]. It has also been suggested that seizures occurring within the first few weeks of 
injury share more in common with early seizures than late seizures, and more data on early 
seizure timing is needed to allow for identification of the point after which the occurrence of an 
early seizure would be predicative of future seizures [81].  To date, Jennett’s classification it is 
still one of the most widely used methods of categorizing PTS. More recently, PTS have been 
typically divided into three categories:  immediate, early and late seizures [32, 78].  Immediate 
seizures are those that occur less than 24 hours after injury. Early seizures occur between 1-7 
days after the injury. Late seizures are those that appear greater than 7 days after the injury.  In 
some studies of PTS, immediate seizures are not included as an early seizure in analysis, while 
other research has shown that both immediate and early onset seizures are risk factors for 
developing LPTS [82]. 
2.2.3 Frequency of PTS 
The frequency of PTS has been well documented in both civilian and military 
populations. Civilian studies have included both clinical studies and population level studies that 
have assessed the frequency of both early and late PTS. Some of the largest population based 
studies to assess risk of seizure were conducted by Annegers et al., as part of the Rochester 
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Epidemiology project in Minnesota.  In their first retrospective cohort they reported on the risk 
of seizures in a cohort of 2747 patients (1132 children and 1615 adults) in Olmstead County, 
Minnesota who had sustained TBI (defined by LOC, PTA, or skull fracture) between 1935-1974 
and were compared with age and sex specific rates of seizure in the general population.  TBI data 
were obtained from physician diagnoses in the medical records [83].  An additional 4541 
children and adults with TBI (characterized by LOC, PTA, or skull fracture) who sustained 
TBI’s between 1975-1984 were added to the second series as a continuation of the project [9]. In 
total they studied post-traumatic seizures for a period of 50 years, with some patients followed 
for over 30 years from the date of their injury.  The overall frequency of PTS was 4.4%, with 
2.6% developing EPTS and 2.1% developing late PTS. Their focus, however, was primarily on 
the risk of developing LPTS. The overall risk of LPTS was 3.6 times higher than in the uninjured 
population. The risk of late seizure was strongly tied to injury severity with the highest risk after 
severe TBI (SIR = 17.0, 12.3-23.6), followed by moderate TBI (SIR = 2.9, 1.9-4.1), and those 
with mild TBI (SIR= 1.5, 2.5-3.8). They also found that late seizure risk was the highest in the 
first year after injury (SIR = 12.7) and fell to 1.4 by 5 or more years after injury.   In the 
univariate analysis, EPTS was a strong predictor of the development of LPTS (Rate Ratio = 5.5), 
but when adjusted for other factors it was no longer a significant independent risk factor for the 
development of late PTS [9]. Thus, seizure risk was highest initially in the most severely injured 
and that risk remained elevated over the course of many years relative to those with more mild 
injuries. 
In a more recent population based study of the development of PTE, Ferguson and 
colleagues conducted a retrospective study of 4519 South Carolina Residents 15 and older who 
had sustained a TBI resulting in hospital admission who were discharged alive between 1999-
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2002.  The cohort was randomly selected based upon hospital size and level of TBI severity.  All 
of the hospitals involved were part of the South Carolina TBI Follow-Up Registry. They 
determined seizure activity from discharge billing and abstraction of TBI related data from 
medical charts. Pre and Post injury seizure activity was assessed via follow-up interviews of 
either survivors or proxies. Of the 4519 patients identified, they excluded 773 due to death, 
deteriorating medical status, incarceration status or other reasons.  There were 3746 patients who 
were eligible to be screened for seizures at one-year post-hospitalization and 1628 declined to 
participate, were unable to be located or were contacted, but did not respond.  
One year after discharge, they were able to interview 2118 patients, at two years they 
interviewed 1536, and at the end of the third year they interviewed 1173. A total of 945 patients 
were lost to follow-up over the course of the three years. Initial reports of seizure activity were 
abstracted from discharge and billing reports, and during the course of the three years, interviews 
were conducted by phone or in person with participants or proxies.  Any evidence of seizure 
activity was documented and confirmed with an epileptologist who was part of the research 
team. A total of 115 patients developed PTE over the course of the three-year follow up.  The 
frequency of EPTS was 3.1% and PTE was 6.2%. They also found that severity of injury greatly 
impacts the risk of developing PTE. The cumulative incidence over the three years of PTE was 
4.4 per 100 persons for those hospitalized with mild TBI, 7.6 for moderate TBI and 13.6 for 
severe TBI, compared to those patients who did not develop PTE.  In addition to injury severity, 
they also found that patients with early PTS, depression, and at least three other comorbid 
conditions were at higher risk for developing PTE [47]. 
 These population-based studies confirm multiple hospital-based studies that have taken 
place over the years. In studies done on patients admitted for head trauma EPTS frequencies 
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range from 4-16% and LPTS frequencies range from 5-25% [33, 43, 45, 48, 84].  While these 
studies differed in how they identified severity, the ages of the population studied, and whether 
they were done in emergency departments or inpatient treatment facilities they all provide a 
general estimate of the frequency of both EPTS and LPTS in regards to TBI.  Another feature of 
all the studies mentioned above is that they have helped determine that a key factor in the 
development in LPTS is the presence of EPTS.  In terms of military populations the overall 
frequency of LPTS ranges from 35%-53% in studies of WWI, WWII, Korean and Vietnam 
veterans [35]. Presumably, the much higher frequency of LPTS in these groups is attributed to 
more severe injuries of a penetrating nature, that result in fracture of the skull, disruption of the 
dural linings, and the retention of bone and metal fragments in the brain [32].  The risk of 
developing LPTS in combat-associated, closed-head trauma with positive brain imaging is 
between about 10-25%, and about 5% without positive imaging findings [34]. While precise 
estimates of LPTS in the current conflicts in Afghanistan and Iraq are unknown, Chen and 
colleagues have estimated that the number of cases of PTE may be over 10,000 by using 
previous estimates of the risk of developing PTE for both penetrating and closed-head injuries 
and based upon the number of soldiers who have already been deployed in these conflicts [34]. 
2.2.4 Treatments for PTS 
 Antiepileptic drugs are often given prophylactically to PTS patients to prevent further 
secondary brain injury and possibly aid in improving their functional outcomes [5]. Chang and 
Lowenstein performed a meta-analysis of the evidence regarding antiepileptic therapy 
prophylaxis in patients with severe TBI by examining and grading prospective studies that 
compared PTS rates in patients receiving these medications compared to controls with severe 
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TBI who did not receive the medications. They pooled studies by their level of evidence based 
upon prospective study design, random or nonrandom level of assignment to AED therapy, 
reporting of PTS in both controls and cases, and publication in a peer reviewed journal. Studies 
were assigned a level of I-IV, with level I studies having a low risk of bias and level IV having 
significant bias.  In four level I and II studies evaluating the risk of developing EPTS; patients 
receiving phenytoin had a significantly lower risk of developing EPTS (RR=0.37, 0.18-0.74) 
compared to controls that either received placebo or no antiepileptic therapy. In their pooled 
analysis of eight Level I and II studies they found that antiepileptic therapy had no significant 
effect in preventing LPTS in severe TBI patients compared to controls who either received 
placebo or no antiepileptic drug therapy. (RR=1.05, 0.82-1.35). The follow-up duration of these 
8 studies ranged from 3 months to 8 years or more [81].  Anticonvulsant medications used to 
treat PTS can produce unwanted side effects, including further neurobehavioral impairment, and 
sedation [10].  Even though it appears that anti-epileptics decrease the rate of early seizures it 
doesn’t appear that there is evidence that the prevention of early seizures affects mortality, 
morbidity, or the development of LPTS [12]. Further work needs to be done to understand the 
underlying risk factors and mechanisms of PTS in order to develop therapies that could identify 
targets for slowing, stopping and more effectively treating seizures [11]. 
2.2.5 Documented Risk Factors 
As described above, one of the most consistent findings across both clinical and 
population based studies has been that injury severity is highly related to the risk of developing 
PTS of all types Many other studies have identified additional consistent risk factors for the 
development of both EPTS and LPTS. 
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In her excellent review of PTS, Frey identified the significant risk factors for both EPTS 
and LPTS from numerous previous studies.  Important independent risk factors for EPTS 
include: acute intracerebral hematoma, acute subdural hematoma (in children), younger age, 
increased injury severity (including LOC, or PTA >30min), and chronic alcoholism. For LPTS 
the significant risk factors included: EPTS, acute intracerebral hematoma (especially subdural 
hematoma), brain contusion, increased injury severity (including LOC or PTA >24 hrs), and age 
>65 [32]. Temkin presented risk factor data from two of their previous studies on seizure 
prophylaxis at the University of Washington as well as other previously documented risk factors 
for PTS.  The two clinical trials included an antiepileptic drug arm and a placebo arm, and were 
based on patients at high risk for developing PTS. The two studies enrolled a total of 783 patients 
within 24 hours of injury and almost all of them received CT scans soon after arrival. Patients 
had to be at least 14 years old, and have had at least one of the following: cortical contusion, 
hematoma (subdural, epidural or intracerebral), depressed skull fracture, penetrating brain injury, 
acute seizures, and for the earlier study a GCS<10. They followed the patients for up to two 
years after their injury as part of the trials.  Among the 196 placebo-treated patients in their high 
seizure risk population they identified the following as risk factors associated with EPTS: 
depressed skull fracture (27%), intracerebral hematoma (23%), subdural hematoma (24%), 
penetrating head injury (20%), GCS<10 (20%), epidural hematoma (17%), cortical contusion 
(16%), and immediate seizures (28%). They only looked at the placebo arm for this analysis, as 
it has been documented that antiepileptic drugs are successful at preventing or suppressing 
EPTS. In terms of developing LPTS, Temkin identified the following subgroups with 
significantly elevated risk:  those with subdural hematoma evacuation, surgery for an 
intracerebral hematoma, GCS between 3-8, early seizures, time to following commands of >1 
 24 
week, depressed skull fracture, dural penetration, at least one non-reactive pupil, and parietal 
lesions on CT scans. She estimated that seizure risk in these subgroups were approximately 400 
times that of the general population based upon data from the Rochester Epidemiology project 
that calculated the cumulative incidence of epilepsy in the general population over the course of 
50 years to be 3% [38, 85]. 
 
2.2.6 Imaging Studies and Animal Models 
As discussed in the previous section injury severity is one of the best predictors of who 
will go on to develop PTS. The presence of intracerebral contusions and subdural hematomas 
have also been identified as significant risk factors for the development of both early and late 
PTS [32, 38].  In a study performed of clinical and EEG factors on the development of PTE in 
civilians with moderate to severe closed-head injuries by da Silva and colleagues, they 
demonstrated that seizures were associated with both younger (<5) and older (>75) ages and that 
the level of neurological deficit (i.e. severity) and lesion location (focal vs. generalized) 
increased the risk of developing PTE [44]. In a recent prospective multicenter study of 
individuals admitted with TBI to four trauma centers within 24 hours of injury, Englander and 
colleagues assessed the natural history and stratified the risks of LPTS for individuals with 
moderate to severe TBI. They enrolled a total of 647 individuals older than 16 years with any of 
the following abnormalities documented by CT scan: extent of midline shift and/or cisternal 
compression or presence of any focal pathology (hemorrhage, contusions, extra-axial lesions) 
during the first 7 days post injury or best GCS score ≤ 10 during the first 24 hours post-injury. 
The subjects were enrolled over a period of three years and followed for up to 24 months, until 
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their death or their first LPTS.  A total of 66 patients had late PTS and they found that the 
highest cumulative probability for LPTS were presence of biparietal contusions (66%), dural 
penetration with bone and metal fragments (62.5%), multiple intracranial operations (36.5%), 
multiple subcortical contusions (33.4%), subdural hematoma with evacuation (27.8%), midline 
shift greater than 5mm (25.8%), or multiple bilateral cortical contusions (25%).  When they did 
risk stratification by the above factors and GCS scores, they found that those with an initial 
moderate GCS score (9-12) had a higher cumulative probability of developing LPTS than those 
with a more severe GCS scores (3-8). They concluded that certain types of TBI put individuals at 
a higher risk for late PTS, and that information from CT scan diagnosis that includes location of 
injury, lesion type, and extent of cortical damage are important factors in assessing patients most 
at risk for developing LPTS or eventual PTE [43].  Temkin also indicated that presence of 
parietal lesions on CT scan were a risk factor for early PTS, but were not an independent 
predictor of LPTS in the analysis of the 196 controls from her two earlier seizure prophylaxis 
studies [38].  A recent review of radiologic and neurophysiologic techniques used to study PTS 
done by Diaz-Arrastia and colleagues indicates that PTS often arises from mesial-temporal 
structures, presumably due to diffuse injury mechanisms that result in damage to vulnerable 
neuronal or axonal populations, or from focal scars in the frontal neocortex resulting from focal 
contusions and intracranial hemorrhages [86].  
 To better understand the underlying etiology of seizure activity that arises after closed-
head injury, several animal models of TBI that use either a fluid percussion technique, or 
controlled cortical impact to simulate moderate to severe closed head injury have demonstrated 
that certain regions of the cerebrum, especially the frontal neocortex and temporal lobes, are 
more likely display seizure activity after brain injury.  In a series of studies using fluid 
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percussion techniques in rats it was demonstrated that frontal parasagittal injuries of the 
moderate to severe category resulted in a high incidence of partial seizures that arose in the early 
weeks after the initial injury [41, 42, 87].  In a population of older rats, a more severe parietal 
fluid percussion injury had a lower incidence of overall epileptic activity and it did not spread to 
the frontal neocortex [40].  Curia et al., conducted a study of rats to examine the effects of 
location and severity of contusive closed-head injury to help elucidate the factors that may 
contribute to some of the heterogeneity seen in human PTS. They concluded that the location and 
severity of injury affects the incidence and severity of seizures, that the frontal cortex is more 
susceptible to PTS than the parietal and occipital lobes, and that there is a wide variation among 
animals in the severity and course of PTS [39]. 
2.2.7 Other Considerations from PTS Studies 
Most studies of PTS have focused on either the natural history of seizure development, 
the relationship of TBI severity to the development of PTS, the use of antiepileptic drugs to 
prevent seizures, or how early seizures can be used to predict the onset of late seizures or PTE.  
Mechanism of injury is usually categorized as motor vehicle, fall, gunshot or other mechanism.  
However, one large prospective study from India followed 520 patients admitted for TBI for 
over a year from the time of injury and reported that of the 59 (11.4%) patients who had 
developed PTS, 6.5% developed immediate seizures, 2.1% developed EPTS and 2.7% LPTS.  
While these results are in agreement with many of the other studies described here, this study 
also reported that the risk of PTS was 3.7 times higher in patients who had fallen from height. 
The authors conclude that since the incidence of gunshot wounds were very low in this cohort (2 
patients) and that most of the vehicular accidents involved pedestrians, which resulted in more 
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mild injuries that this may be an artifact, but the result did hold up in the multivariate analysis of 
their study.  They also looked at a variety of outcome measures related to those who developed 
PTS and those who did not and found that those with PTS were more likely to have poorer 
behavioral outcomes and GOS scores at the end of follow up [46]. Other studies have also 
looked at outcome measures in those with and without PTS after head injury.  In a prospective 
study of 210 patients, Marwitz and colleagues found there were no significant differences in 
outcomes at 1 year post-injury in those with PTS and those without [88].  A study done by 
Asikainen et al. followed 490 TBI patients for 5 years or more from the time of injury through a 
rehabilitation and reemployment program in Finland.  They found that while LPTS did worsen 
functional outcome as measured by GOS, it had no significant influence on reemployment at the 
end of the follow-up period [48].  Additionally, late occurring seizures have also been associated 
with greater psychiatric problems, reduced general health and poorer functional and social 
outcomes [12]. 
 The previous paragraphs have documented that PTS is highly heterogeneous in nature 
and has been proposed to depend on variation in the type, location, severity, number of injuries, 
secondary brain insults, ages, genders and different genetic backgrounds of the patients [36, 79].  
One very important potential mechanism that may determine who does and does not develop 
PTS is the role of genetic susceptibility. Currently, it is far from understood and there is a wide 
range of variability in responses to similar injuries with some patients seizing frequently and 
others not at all. As early as 1979, Caveness wrote that there is likely to be a “constitutional 
tendency towards PTS (probably a multifactorial genetic trait) and brain damage” [79]. 
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2.2.8 Genetic Susceptibility as a PTS Risk Factor 
While the number of epidemiologic studies of PTS has grown substantially over the past 
several decades, there is still much work to be done to understand the risk factors and 
mechanisms that underlie PTS. One very important mechanism is the role of genetic 
susceptibility. Currently, it is far from understood and there is a wide range of variability found 
in responses to similar injuries with some patients seizing frequently and others not at all [32]. In 
the past two decades there have been several genes implicated as influencing outcomes after TBI 
(including, but not limited to PTS), and future studies will most likely identify even more genes 
that modulate recovery or provide neuroprotection from TBI [50]. Other recent studies have 
explored genetic susceptibility to seizure disorders [14, 15], and treatment outcomes after TBI 
[89]. 
 APOE is by far the most widely studied in regards to TBI. APOE encodes for a 
cholesterol carrier lipoprotein and exists in three allelic forms E2, E3 and E4. APOE E4 in 
particular has been identified as a susceptibility gene for late onset and familial Alzheimer’s 
disease [90]. Other established neurobiological functions of APOE include:  amyloid plaque 
deposition, neurofibrillary tangle formation, antioxidant activity, neuronal repair, cholesterol 
transport, synaptic plasticity and neuroprotection [50].  There have been numerous studies to 
support the hypothesis that APOE allele status influences outcome after TBI, in particular that 
those individuals carrying at least one copy of the APOE E4 allele have poorer outcomes, longer 
hospital stays, and worse rehabilitation outcomes [50]. The adenosine A1 receptors (A1AR) are 
found primarily in neurons and are the high affinity target for adenosine and have been 
implicated in TBI neuroprotection by limiting excitability of neurons, and in traumatic and 
non/traumatic seizure development in multiple experimental models [19].  Haptoglobin (Hp) is 
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polymorphic and three major phenotypes exist.  The primary job of haptoglobin is to bind free 
hemoglobin, and remove it from the damaged tissues after microhemorrhage events and its levels 
have been shown to increase after TBI [17].  The GRIN2a (glutamate receptor subunit epsilon 1) 
gene codes for a portion of a ligand gated channel and plays a role in excitatory synaptic 
transmission particularly after neuronal injury.  The GAD1 and GAD2 genes code for enzymes 
that create two different isoforms of glutamic acid decarboxylase (GABA), which acts as an 
inhibitory neurotransmitter at the postsynaptic membrane.[18]  The apolipoprotein E (APOE) 
gene is also one of the most studied in terms of PTS [16, 20, 50].  For example, the long term 
Vietnam Head Injury study (VHIS) screened for APOE E4 genotypes in regards to PTE [18].  
Anderson et al, 2009 investigated relationships between PTS and APOE as well as PTS and 
haptoglobin phenotypes [17].  Even more recently, those carrying two copies of APOE 4/4 were 
more likely to have to late PTS (19). In the following section, 5 studies of nuclear genes and their 
realtionship to PTS will be reviewed. 
  Diaz-Arrastia et al. conducted a study to examine the association between a specific 
genetic variant and the development of PTS. They utilized a prospective design in which subjects 
were recruited from a level 1 urban trauma center between January 1999 and December 2001. 
Their purpose was to determine if inheritance of the APOE 4 allele was associated with the risk 
of developing LPTS in a population of patients who had suffered a moderate to severe brain 
injury.  Inclusion criteria included any one or more of the following: evidence of cerebral 
contusion on CT, any intracranial hematoma, depressed skull fracture, penetrating brain injury, 
or EPTS occurring less than one week after injury. Patients with pre-injury epilepsy, previous 
neurologic conditions, nontraumatic hemorrhage, or major cortical infarction were excluded. A 
total of 204 patients met the criteria for enrollment and outcome questionnaires were collected 6 
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months after injury on 106 patients.  The authors explained that this type of loss to follow-up is 
not uncommon in TBI studies and they found no differences in major demographic and clinical 
characteristics of the 98 patients lost to follow-up compared to those who went on to develop 
PTS in the study, but did note that there was a slight trend towards less severe injury in those 
who did not complete the 6 month follow-up questionnaire. Of the 20% (21/106) of patients who 
developed LPTS they found no significant differences due to age, sex, ethnicity, initial GCS 
scores, length of stay, discharge status or Glasgow Outcome Status (GOS) to those who did 
develop PTS.  The only two significant covariates identified were the presence of EPTS (within 
1 week of injury) and the presence of at least one copy of the APOE 4 allele.  In their final 
adjusted model, the risk of developing PTS was 2.41 (1.15-5.07; p=0.03) in patients who carried 
at least one copy of the APOE 4 allele. Their sample size was too small to evaluate if carriage of 
two APOE 4/4 alleles conferred a greater risk [16]. 
 Anderson and colleagues performed a matched case control on a group of patients who 
had previously taken part in a double blind controlled trial on the effectiveness of anti-epileptic 
drugs in the early 1990’s [10].  The Diaz-Arrastia study mentioned in the previous paragraph 
modeled their inclusion and exclusion criteria on the patients from the original clinical trial; 
therefore, there were similarities in both of their cohorts.  The purpose of this study was to 
investigate if there was any genetic predisposition to develop PTS in cases based upon their 
haptoglobin phenotype or their APOE allele status. For the APOE analysis they were seeking to 
expand upon the earlier work of Diaz-Arrastia and colleagues.  Haptoglobin phenotype was 
chosen because its main biological function is to bind free hemoglobin and facilitate its excretion 
from the body and accumulation of hemoglobin and iron residues after TBI are known to be 
epileptogenic. The Haptoglobin gene codes for three haptoglobin genotype (Hp 1,1, Hp 2,2, and 
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Hp 2,1) that vary widely in their ability to bind free hemoglobin and they hypothesized that those 
with less ability to clear hemoglobin would be at higher risk for seizures. The original clinical 
trial examining the effects of antiepileptic drugs on PTS development had enrolled a total of 379 
patients of whom 56 went on to develop late PTS. Samples used in this study were collected as 
part of the 10-year follow-up to the original trial or from frozen serum samples from when the 
trial took place. 25 subjects from the original late PTS group who returned for follow-up became 
the cases and were matched on age, sex and PTS risk factors with 26 controls with no evidence 
of late PTS from the original trial.  In addition, they were able to obtain haptoglobin phenotypes 
from frozen serum samples of 25 additional patients who developed PTS and 32 matched 
controls with no evidence of PTS in the initial trial. For the APOE analyses they had a total of 25 
cases and 26 controls and unlike the Diaz-Arrastia study they did not find any association 
between the carriage of the APOE 4 allele and greater risk of PTS. For the haptoglobin portion of 
their analyses they had a total of 50 cases of PTS and 58 matched controls.  They found no 
significant difference in the odds of developing PTS based upon haptoglobin phenotypes in long 
term survivors of TBI [17]. 
Miller et al. performed a study on 322 patients with severe closed-head TBI who were 
enrolled as part of a larger cohort study at the University of Pittsburgh Medical Center studying 
the effects of APOE genotype on outcomes after TBI.  Patients were enrolled into the cohort if 
they were between 18-75 years of age, had a GCS<8 with positive findings of trauma on CT 
scans and required extraventricular drainage and intracranial pressure (ICP) monitoring. Patients 
with penetrating head injury as well as those with prolonged cardiac or respiratory arrest were 
excluded.  Information about PTS was collected through abstraction of medical records.  The 
primary measure in this study was time to first seizure. PTS was divided into three categories, 
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early late and delayed onset.  EPTS were those recorded within the first week of injury, LPTS 
occurred after 1 week, but before 6 months, and delayed onset PTS occurred 6 months or greater 
after the initial injury. There were a total of 235 subjects in the early PTS group who had both 
APOE genotype information and medical record information. Of this group, 16 developed 
seizures. Chi square analysis showed no significant association between APOE genotype and 
EPTS (p=0.479). Subjects with APOE 2 or APOE 3 alleles had no difference in EPTS rates 
compared to those who did not have the alleles, nor was the APOE 4 allele significantly 
associated with EPTS. There were 216 subjects in the LPTS group who had both APOE 
genotype information and medical record information.  A total of 44 patients in this group 
developed seizures.  None of the subjects who were E2/E2 or E2/E4 developed late PTS, and 
carriage of the E2 allele (p=0.126) or E3 allele (p=0.667) also did not predispose one to LPTS.  
Those carrying only one copy of the E4 allele did not show any increased odds of developing 
LPTS (p=0.430), however, the most intriguing finding was that they noted that half of patients 
who carried the APOE 4/4 developed late seizures. The authors do caution, however, that this 
was an extremely small group of subjects (n=5).  There were a total of 196 patients in the 
delayed onset PTS group who had both APOE and medical record information. A total of 24 of 
these patients developed seizures.  Similar to the LPTS group, those who were E2/E2 and E2/E4 
had no evidence of PTS, and selecting for the E2 or E3 allele alone showed no greater odds of 
developing delayed onset PTS. There were also no differences in delayed onset PTS for subjects 
with or without the E4 allele (p=0.803) [20]. 
Working from the same population of patients, utilizing the same inclusion and exclusion 
criteria, and the same definitions of PTS as Miller et al., Wagner and colleagues studied whether 
variability in the adenosine A1 receptor (A1AR) gene was related to the development of PTS. 
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They identified 206 patients with both A1AR genotype information and medical record 
information regarding PTS.  From this group, they removed those with evidence of premorbid 
seizure and non-caucasians (due to extremely small numbers), and analyzed a total of 187 
patients to determine if genetic variability within the Adenosine A1 receptor (A1AR) gene and 
its flanking region were associated with the development of PTS.  Adenosine and its receptor 
subtypes have been implicated as important factors in the secondary neurobiological cascade of 
injury that occurs after TBI. This study explored the A1AR gene by looking at tagging SNPs 
(tSNPs) that when analyzed are capable of capturing variability within the gene itself and the 
related flanking regions.  5 tSNPs were explored, and two of them, rs3766553 and rs10920573 of 
the A1AR gene were significantly associated the onset of PTS after adjusting for other covariates 
known to influence PTS.  The AA genotype of rs3766553 was associated with EPTS (p=0.05) 
and the GG genotype of rs3766553 was associated with LPTS (p=0.019). The heterozygous CT 
genotype of rs10920573 was associated with LPTS (p=0.039). Those patients who had both the 
GG rs3766553 and CT rs10920573 genotypes had higher odds (OR = 13.124, p=0.001) of 
developing late PTS and higher odds (OR=28.869, p=0.005) of developing delayed-onset PTS 
[19]. 
Raymont et al. examined whether selected genetic markers from several candidate genes 
were associated with the development of seizure activity (defined as PTE in this study) in a long 
term follow-up of subjects enrolled in the Vietnam Head Injury Study (VHIS). Phase 3 follow-
ups were conducted 35 years post injury on 199 veterans who had suffered primarily penetrating 
head injuries. 43.7% (87/199) reported seizure activity and 12.6% (11/87) of those developed 
PTE between the phase 2 visit 15 years earlier and the phase 3 follow-up.  They screened for a 
number of genetic markers that had been associated with epilepsy in previous studies.  The 
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markers selected for their analyses included: the presence of APOE 4 allele, glutamic acid 
decarboxylase (GAD), catechol-O-methyltransferase (COMT), GRIN (a glutamate receptor 
subunit), BDNF (brain derived neurotrophic factor) and DBH (dopamine B-hydroxlyase). In 
their initial analyses they found that the SNP rs11074504 of GRIN2a (p=0.007), SNP rs1330582 
of GAD2 (p=0.019), and SNP rs769395 of GAD1 (p=0.053) were significantly associated with 
PTE. However, when the authors corrected for multiple comparisons, none of the SNPS retained 
their significance. They also found that carriage of the APOE E4 allele did not impact the 
development of PTE (p=0.34), nor did any of the variants in COMT, BDNF, or DBH [18]. 
The papers reviewed here show that there is a growing trend to investigate and elucidate 
the impact of genetic variants that are thought to underlie the development of PTS.  A better 
understanding of the genetic contribution may lead to new treatments that could disrupt the 
mechanisms that contribute to PTS and result in more effective management of this common 
complication of TBI.  These trends indicated by the papers reviewed here also highlight the need 
for investigation of the genetic variants in larger, multi-center cohorts that can achieve the 
sample sizes and power necessary to detect the true impact of these variants on the development 
of PTS. 
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2.3 MITOCHONDRIA AND SEIZURES 
2.3.1 Mitochondria 
Mitochondria are membrane bound organelles that lie within the cytoplasm of most 
eukaryotic cells. They are typically depicted as fusiform organelles that consist of a smooth outer 
membrane and a highly folded inner membrane that is referred to as the cristae.  In reality they 
are much more than static organelles and can be thought of as a budding and fusing network 
similar to that of the endoplasmic reticulum [21]. Their shape varies in response to 
environmental demands and cellular differentiation [91]. Their numbers within cells vary based 
upon demand with high energy cells like muscle, kidney, liver and neurons having hundreds of 
copies and red blood cells having none [92].  In terms of function they are involved in cellular 
homeostasis where they play crucial roles in intracellular signaling, apoptosis, intermediary 
metabolism, and in the metabolism of amino acids, lipids, cholesterol, steroids, and nucleotides 
[21]. However, they are most often described as the power plant of the cell because they generate 
the majority of ATP needed to perform normal physiologic functions [92].  
ATP is generated during cellular metabolism through the addition of a phosphate group 
to an adenosine diphosphate (ADP) molecule resulting in in a high energy molecule.  When the 
terminal phosphate bond is transferred from ATP to other molecules, energy is released that can 
be used to do work within cells.  Cells can create ATP through substrate level phosphorylation 
and oxidative phosphorylation (OXPHOS) [92].  Substrate phosphorylation occurs in situations 
such as glycolysis when glucose is cleaved into phosphorylated intermediaries that then transfer 
those phosphates to ADP molecules within the cell.  Glycolysis is not very efficient as typically 
only two usable ATP are created for each molecule of glucose.  Oxidative phosphorylation 
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(OXPHOS) is much more efficient, with electrons being harvested from nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) which are the intermediaries of 
glucose cleavage that occur within the mitochondrial membranes (Kreb’s cycle and electron 
transport chain) and then used to generate much larger amounts of ATP for each glucose 
molecule.  Most cell types utilize both types of energy production.  The majority of the reactions 
necessary for OXPHOS occur on a group of enzyme complexes that lie on the inner 
mitochondrial membrane and are most often referred to as the mitochondrial respiratory chain or 
the electron transport chain (ETC) enzymes [21]. 
 There are a total of five enzyme complexes (Complexes I – V) that are embedded into the 
inner mitochondrial membrane, and each one is composed of multiple polypeptide subunits. 
Complex I consists of over 40 subunits, Complex II has 4 subunits, Complex III has 11 subunits, 
Complex IV has 13 subunits, and Complex V has 16 subunits. In addition to these large 
enzymatic complexes, there are also two electron carriers, ubiquinone (coenzyme Q10) and 
cytochrome c [93]. The NADH and FADH2 intermediaries created during aerobic respiration act 
as reduced cofactors that donate hydrogen to complexes I and II.  As the hydrogen molecules 
pass through the complexes, their electrons are stripped and are shuttled down an 
electrochemical gradient via the mobile electron carriers to complexes III and IV and are 
eventually transferred to molecular oxygen where they will produce water.  At the same time, the 
H+ ions that have been stripped of their electrons are pumped into the intermembrane space 
creating the mitochondrial membrane potential. The accumulated H+ ions move from the 
intermembrane space back into the inner matrix through complex V (ATP synthase), and as they 
do complex V rotates and adds inorganic phosphate to ADP to create ATP [93].  These enzymes 
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complexes are crucial to energy production throughout the body and mitochondria have unique 
characteristics not seen elsewhere. 
2.3.2 Mitochondrial DNA (mtDNA) 
 The most unique aspect of mitochondria is that they contain their own DNA (mtDNA) 
that is separate from nuclear DNA (nDNA) [94]. The complete human mtDNA sequence was 
published in 1981 and is referred to as the Cambridge Reference Sequence [26]. The 
mitochondrial genome is very different than the nuclear genome in that it is a small 16.569kb 
circle of double stranded DNA with 37 genes that code for the transfer RNA (tRNA), ribosomal 
RNA (rRNA), and the polypeptide subunits of respiratory complex enzymes (Complexes I, III, 
IV and V). 13 genes from mtDNA code for the following subunits of complexes I, III, IV and V: 
Complex I has ND1, ND2, ND3, ND4, ND4L, ND5, and ND6.  Complex III has the cytochrome 
b (cytb) component. Complex IV contains the COX I, II, and III subunits. Complex V contains 
the ATP6 and ATP8 units of the ATP synthase enzyme. The only respiratory chain enzyme 
complex with no contribution from mtDNA is complex II [21]. 22 genes code for transfer RNA 
molecules necessary to assemble the respiratory complex enzymes, and two genes code for 
rRNA molecules necessary for protein translation [26]. Mitochondria are the only organelles 
outside the nucleus that contain their own DNA and the ability to synthesize their own RNA and 
proteins.  Depending on the cell type there can be hundreds to thousands of mitochondria per cell 
and each one contains approximately five mitochondrial genomes. It is known that there are 
approximately 900 gene products in the mitochondria, many more than is encoded by the 37 
genes found in the mtDNA.  The vast majority of the respiratory complex enzymes are encoded 
for by nDNA [93, 95].  
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A typical human cell can have 100 or more mitochondria, each with approximately five 
copies of their mtDNA. In a normal individual, these copies are identical (homoplastic).  
However, individuals with a mutation in their mtDNA often have a combination of both normal 
and mutated mtDNA in their cells and this is termed heteroplasmy [96]. The amount of mutated 
mtDNA can vary widely from person to person, organ to organ, or even between individual cells, 
causing a threshold effect in which a certain percentage of mutated mtDNA must be present 
before symptoms of mitochondrial disease are evident [93]. If the abnormal amount of mtDNA 
copies exceeds a certain level, then the normal mtDNA can no longer compensate and the 
symptoms of the mitochondrial disease are expressed [97]. This is particularly evident in organs 
that rely heavily on mitochondrial energy production such as the eyes and central nervous system 
[98].  
mtDNA is maternally inherited with the oocyte passing their mitochondria to offspring 
[99]. If a mother contains a mutation in her mtDNA she will pass it on to all of her children, but 
it will only continue to be passed on by her daughters.  This has allowed large family pedigrees 
to be created that have been helpful in understanding the clinical variability seen among siblings 
of an affected mother [100]. mtDNA is not tied to the cell cycle like nDNA and is able to 
replicate continuously, even in nonmitotic tissue like skeletal muscle and the brain. In a 
heteroplasmic cell this may allow mutated mtDNA to replicate at different rates than normal 
mtDNA either due to random chance or some selective pressure. [21].  This could account for 
some of the late onset and clinical variability seen in mtDNA diseases [101]. 
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2.3.3 Mitochondrial Diseases 
According to Dimauro, the term “mitochondrial disease” refers to disorders of the 
mitochondrial respiratory chain enzymes that are under the dual control of both mtDNA and 
nDNA. He states that genetic classifications of mitochondrial disease distinguish those disorders 
that are due to mutations in mtDNA from those that are due to defects in nDNA. The mtDNA 
mutations can be divided into those that impair one of the 13 respiratory chain proteins encoded 
by mtDNA or those that affect mitochondrial protein synthesis in total that also includes the 22 
tRNA and 2 rRNA genes [102]. For the purpose of this review, the focus will be only on those 
diseases that are associated with alterations in mtDNA that affect the functioning of the 
respiratory complex proteins. 
Mitochondrial diseases were once thought to be extremely rare, but in the past decade 
several population based studies have shed light on the incidence and prevalence of 
mitochondrial disease.  Majamma and colleagues examined the medical records in northern 
Finland to identify a cohort of adults with clinical features suggestive of mitochondrial disease in 
population of 245,201.  They did extensive genetic testing and family tree analysis and gave a 
minimum point prevalence of one of the most common mtDNA mutations, the A3243G 
transition.  They estimated the prevalence of mutation to be 16.3/100,000 (95% CI 11.3-
21.4/100,000) in the general population. Upon further analysis of those carrying the A3243G 
mutation they found a disease prevalence of 5.71/100,000 for conditions that included 
hypertrophic cardiomyopathy, deafness, and diabetes mellitus [103].   
Chinnnery and colleagues based their study on adults referred with suspected 
mitochondrial disease over a 15 year period to their center in northeast England, which serves a 
population of over 2 million.  Through clinical, biochemical, and genetic studies, they 
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determined the prevalence of mitochondrial diseases to be 6.57/100,000 (95% CI = 5.30-7.83), 
and through extended family studies of affected patients were able to determine a mutation 
prevalence of 12.48/100,000 (95% CI = 10.75-14.23) [104]. Darin et al. [105] conducted a study 
of 358,616 children over a 15 year period in Sweden and found a minimum prevalence of 
4.7/100,000. In another study done in Australian children referred to Melbourne Children’s 
hospital over a 10 year period, Skladal and colleagues estimated the minimum prevalence of 
childhood respiratory chain disease to be 4.7/100,000 (95% CI = 3.2-5.0) in a population of 
1,710,000 [106].  In a recent review of the epidemiological literature regarding mitochondrial 
disease, Schaefer estimated the combined prevalence of childhood and adult mitochondrial 
disease to be as high as 20/100,000 across all known mtDNA mutations thus far studied. [107]. 
The first pathogenic mutations of mtDNA were reported in 1988 [108, 109].  Since that 
time over 200 different pathogenic point mutations of the mitochondrial genome have been 
identified as well as other large scale rearrangements of the mitochondrial genome [110]. One of 
the major databases for collecting and disseminating information regarding the mitochondrial 
genome and variation is MITOMAP: A Human Mitochondrial Genome Database 
(http://www.mitomap.org, 2011).   
Diseases that are due to defects in mtDNA affect a cell’s ability to produce energy 
through OXPHOS reactions and often result in proliferation of both normal and mutated 
mitochondria within the affected cells, which gives them a characteristic ragged red fiber look 
[111]. This is also often accompanied by increased production of lactic acid as the affected cells 
resort to substrate phosphorylation for energy production [112].  Additionally, mitochondria are 
known to produce the majority of reactive oxygen species (ROS) in cells [113].  Mitochondria 
are especially susceptible to damage due to ROS because unlike nDNA, mtDNA has limited 
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repair capabilities [114].  Damage to mtDNA creates a cycle of worsening mitochondrial 
dysfunction and increased ROS production [30].  According to Calabrese, mtDNA mutations 
lead to impairment of the respiratory chain enzyme functioning, which leads to decreased ATP 
production, increased formation of toxic free radicals, and altered calcium homeostasis [115].   
  Wallace states that mitochondrial diseases are heterogeneous, often multisystemic, and 
tend to affect tissues with high energy demands, such as the brain, muscle, heart and endocrine 
systems. The energetic deficits of altered mitochondrial function have been implicated in forms 
of blindness, deafness, movement disorders, dementias, cardiomyopathy, renal dysfunction and 
aging [116]. A comprehensive list of diseases associated with mtDNA mutations organized by 
phenotype can be found at MITOMAP (http://www.mitomap.org, 2011). 
2.3.4 mtDNA and Seizures 
According to Waldbaum and Patel, mitochondrial dysfunction and oxidative stress 
contribute to several neurologic disorders, and have been implicated in both inherited and 
acquired epilepsies [52].  Inherited epilepsies are those caused by mutations in either the nDNA 
or mtDNA and it is known that many inherited mitochondrial diseases include seizure as part of 
their pathogenesis [22, 117].  Acquired epilepsies are thought to account for up to 60% of all 
epilepsies and are typically initiated by a brain injury (trauma, ischemia, hypoxia, etc.)  followed 
by a “latent period” in which molecular, biochemical and other cellular alterations occur leading 
to chronic epilepsy [52].  In one study it was found that seizures were the first recognized sign of 
a mitochondrial disorder in 53% of the patients they examined [23].  Two of the most studied 
mitochondrial diseases that exhibit seizure are Myoclonic Epilepsy with Ragged Red Fibers 
(MERRF) and Mitochondrial Myopathy Encephalopathy, Lactic Acidosis and Stroke (MELAS).  
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MERRF can be caused by several different point mutations in mtDNA, with clinical hallmarks 
that include progressive epilepsy and a distinct appearance of mitochondria in muscle fibers [24]. 
MELAS syndrome can be caused by multiple mtDNA point mutations and has clinical features 
that include seizures, hemiparesis, hemianopia, and blindness among others [25].  
In preparation of this review, an initial search was performed on mtDNA and seizures, 
and returned several excellent reviews that have compiled tables of some of the more common 
mtDNA point mutations that have been associated with epileptic phenotypes [22, 53, 54]. In an 
effort to get the most complete picture of mtDNA point mutations that have been associated with 
seizure phenotypes, the MITOMAP database was accessed between 5/13/11 and 6/05/11 for the 
initial searches and again on 8/20/11 for updates (http://www.mitomap.org, 2011).  There are 
two databases within MITOMAP that have a comprehensive list of all the mtDNA mutations, 
associated diseases, clinical phenotypes, and link to the original source articles. 
1. Diseases associated with mtDNA mutations in the 22 tRNA and 2 rRNA genes  
 (tRNA, rRNA link)  
2. Diseases associated with mtDNA mutations in the 13 respiratory protein coding regions 
(coding region link).   
There were a total of 257 articles in the two databases and the same review criteria were 
applied to both databases. In order to be included for this review, the articles had to include the 
following information: The affected patient(s) had to have seizures as part of their clinical 
presentation. The articles also had to include a discussion of the pathogenicity of the mutation.   
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There are well accepted criteria for pathogenicity of mtDNA mutations that include:  
1.  The mutation should not be found in normal individuals of the same ethnic group. 
2. It should alter a site that has been conserved evolutionarily (i.e. it is functionally important 
and not novel).  
3. It should cause single or multiple respiratory chain deficiencies.  
4. There should be a correlation between the amount of mutant mtDNA and clinical severity  
(Adapted from Dimauro, 2010 [118], and Chinnery, 1999 [119]). 
Articles were not included for review if seizures or epilepsy were not documented as part 
of the clinical presentation. If the clinical presentation was due to an insertion or deletion rather 
than a point mutation it was not included (there were a total of 3 articles excluded for this 
reason). 
From the clinical phenotype database for the 22 tRNA and 2 rRNA genes responsible for 
protein assembly inside the mitochondrion, a total of 176 articles were reviewed and 31 different 
mtDNA point mutations met the criteria listed above. Mutations deemed to be pathologic in 
causing clinical phenotypes that included seizure were noted in 13 different genes.  A list of the 
primary articles with the associated mutation in the tRNA or rRNA genes is included in 
Appendix A. The tRNA genes with identified mutations were: Asparagine (MT-TR), Glutamic 
Acid (MT-TE), Glutamate (MT-TQ), Glycine (MT-TG), Histidine (MT-TH), Isoleucine (MT-
TI), Leucine (MT-TL), Lysine (MT-TK), Phenylalanine (MT-TF), Serine (MT-TS), Threonine 
(MT-TT) and Valine (MT-TV). The one rRNA assembly gene with an identified mutation was 
16S (MT-RNR2).  The tRNA regions with the most documented mutations related to seizure are 
the Leucine and Lysine genes, and the most common clinical conditions associated with them are 
MERRF and MELAS.  
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From the clinical phenotype database of mutations affecting respiratory enzyme coding 
region genes, a total of 81 articles were reviewed and there were 20 different mtDNA mutations 
that met the criteria of having seizure as part of the phenotype. Mutations were noted in 9 
different genes of the 13 total genes in the mtDNA that code for proteins of the respiratory 
complex enzymes. In Complex I, mutations that associated with seizure were found in the ND1, 
ND3, ND4, ND5 and ND6 genes. In Complex III, mutations were found in the cytochrome b 
gene. In Complex IV, mutations were found in the COX I and COX III genes. In Complex V, 
mutations were found in the ATP6 gene that associated with seizure phenotypes. A list of the 
primary articles with the associated mutations in the respiratory protein coding genes is included 
in appendix B.  Complex I subunits appear to be hotspots for mutation related to seizure activity.  
10 different mutations with seizure phenotypes were noted in the ND1-ND6 subunits. 
Seizures appear to be an extremely common component of many mitochondrially inherited 
diseases. This finding is not unexpected, given that mitochondrial diseases often manifest in 
those tissues with the highest energy demands (i.e. brain or muscle). However, the role that 
altered mtDNA and the associated mitochondrial dysfunction play in the 60% of acquired seizure 
disorders (i.e. PTS) remains to be explored [52]. 
2.3.5 mtDNA Variants as Risk Factors for PTS 
Post-traumatic seizures are a form of acquired seizures that are a common and often 
debilitating consequence of TBI. Numerous risk factors have been identified in both clinical and 
population based studies of PTS, and recent work has begun to investigate the role that specific 
nuclear genetic variants may play in the risk of developing PTS. Over the past few decades, 
numerous variations in the mitochondrial genome have been identified that lead to disrupted 
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energy production, oxidative stress, and homeostatic imbalance.  High energy tissues like the 
brain are particularly susceptible.  Additionally, many mitochondrial disorders exhibit seizure 
phenotypes as part of their pathogenesis and mitochondrial variants have been implicated in 
contributing to both inherited and acquired forms of epilepsy.   
 To date no work has explored the possible association between mtDNA variants and the 
risk of developing PTS. In reviewing the current literature, only one other study was found that 
explored variation in the mtDNA genome as a risk factor for acquired injury.  Canter and 
colleagues performed a prospective study on 745 patients admitted to the trauma intensive care 
unit at Vanderbilt University Medical Center between April 2005 and February 2007.  All 
patients admitted to their level 1 trauma center were potentially eligible for the study.  However, 
those younger than 18, prisoners, those with known pregnancy, and those that expired before 
admission into the trauma ICU were excluded from the study.  All eligible patients had blood 
drawn within 24 hours of admission to the trauma ICU.  A total of 666 patients had DNA 
extracted from a blood sample. Detailed demographic and clinical covariates were obtained at 
the time of admission. They sought to determine whether specific genetic variations in mtDNA 
known to impact energy production were associated with the risk of in-hospital mortality after 
severe trauma as assessed by Injury Severity Scores (ISS) They selected three mtDNA 
polymorphisms at positions 4216, 10398, and 4917 because variants are known to alter the 
amino acid sequence of key subunits of the Complex I enzyme of the respiratory chain. They 
demonstrated that one mtDNA variant (the 4216 T allele) was an independent predictor of 
increased mortality in the multivariate model [30]. While the study did not focus on TBI or PTS, 
their findings imply that mtDNA variants can be useful as predictors of outcome after injury. 
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2.3.6 Summary 
Traumatic brain injury (TBI) represents a major public health issue with some 1.7 million 
people sustaining TBI annually in the United States [1]. Between 3.2-5.3 million people suffer 
from the long term sequelae of TBI that include reduced quality of life, and the loss of one or 
more physical or mental functions [3], and up to $60 billion is spent yearly to cover health 
expenses and lost wages due to TBI [31]. 
One common and potentially debilitating consequence of TBI are post-traumatic seizures 
(PTS), which are seizures that occur after head injury and thought to be causally related to the 
trauma itself [32]. The probability of developing PTS is significantly correlated to the type 
(closed versus penetrating) and severity of TBI (mild, moderate and severe). The prevalence of 
PTS ranges from as high as 53% in military populations with penetrating TBI [35], to 
approximately 10-15% among civilians with severe TBI [9]. 
PTS is a heterogeneous condition and it has been proposed to depend on variation in the 
type, and severity of injuries as well as on the different genetic backgrounds, ages and genders of 
the patients [36, 37].  Injury severity is by far the best predictor of who will go on to develop 
PTS [32, 38]. Lesion type and lesion location have also been associated with the development of 
PTS in several human studies [38, 43-45].  PTS may also play a role in moderating functional 
outcomes after TBI.  PTS has been associated with poorer GOS scores and higher incidence of 
behavioral abnormality in patients with severe TBI [46].  Late PTS has also been associated with 
a higher incidence of depression [47]. A 5 year prospective study of rehabilitation and 
reemployment in Finland showed that late PTS was associated with poorer functional and social 
outcomes and was a considerable factor in hospital readmission [48]. Overall, it appears that PTS 
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can result in greater psychiatric problems as well as reduced general health and poorer functional 
and social outcomes [12]. 
Studies exploring genetic susceptibility to seizure disorders have expanded significantly 
the number of potential candidate genes involved with seizures [14, 15, 49], while others have 
begun to expand the concept of genetic susceptibility to TBI outcomes [50, 51]. Only recently 
have genetic studies revealed that several nuclear genetic variants (APOE, A1AR, GAD) may act 
as risk factors in the development of PTS [16-20]. While no studies have yet to focus on the role 
of mitochondrial DNA in the development of PTS, strong evidence has emerged that variations 
in the mitochondrial genome are linked to mitochondrial encephalopathies that have disrupted 
cellular metabolism and seizure as part of their phenotype [52-54]. 
The goals of this proposed project are to use data from our cohort of severe TBI patients 
to explore roles that mtDNA variants may play as independent risk factors for the development 
of both early PTS (EPTS) and late PTS (LPTS) (Aim 1). To explore whether mtDNA variants 
act as effect modifiers of other injury related factors (mechanism, lesion type) in relation to the 
development of EPTS or LPTS (Aim 2), and to explore if mtDNA variants affect the relationship 
between LPTS and functional outcome measures (GOS) at 6 months post-injury (Aim 3). 
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3.0  METHODS 
3.1 STUDY POPULATION AND VARIABLE SELECTION 
3.1.1 Setting 
Subjects included in this research were recruited at the University of Pittsburgh Medical 
Center (UPMC), a Level I accredited regional trauma center with 816 beds and an NIH (NS: 
30318) funded Head injury Clinical Research Center (Brain Trauma Research Center: BTRC). 
The BTRC has worked closely with the neurotrauma intensive care unit (NTICU) of UPMC 
since 1991 collecting data on severe head injury patients.  This close partnership has led to a 
cohort of well characterized TBI patients with extensive biological, genetic, demographic and 
functional outcome data available through the BTRC databases. 
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3.1.2 Subjects 
All subjects who were admitted to the Emergency Department of UPMC Presbyterian 
were considered for inclusion if they met the following criteria of severe TBI: 
Inclusion criteria: 
1.  Severe TBI (Glasgow Coma Scale < 8). 
2.  Age 18-75 years old. 
3.  Positive findings on head CT scan. 
4.  Required extra-ventricular catheter for drainage and intracranial pressure monitoring. 
Exclusion criteria: 
1.  Any pre-existing neurologic diseases or deficits 
2.  Significant cardiac or respiratory arrest before hospital admission. 
3.  Severe TBI due to penetrating injury.   
3.1.3 Critical Care Management 
 All subjects admitted to the BTRC through the NTICU received treatment as defined by 
The Guidelines for Management of Severe Head Injury [66]. CT scans were performed to 
identify intracranial lesions or hemorrhages.  Each patient had an extra-ventricular catheter, a 
venous catheter and arterial catheter placed upon admission.  If necessary, decompressive 
craniotomy was performed. Any elevation in intracranial pressure (ICP) was treated to maintain 
normal levels (<20mmHg) and cerebral perfusion pressure (CPP) was maintained at >60mmHg. 
However, if CPP remained low, then mean arterial pressure (MAP) was raised with appropriate 
medications to maintain a MAP >90mmHg.  Standard EEG monitoring was ordered 
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intermittently for patients with suspicion of seizure activity. Most patients enrolled received anti-
seizure prophylaxis for 1 week post-injury [20]. 
3.1.4 Sample Size 
Sample Size: (n=336 for 6 SNPs, n=136 for 19 SNPs): 
 
 The samples for this study were collected from patients enrolled with additional consent 
for genetic analysis into the BTRC as part of a study that was conducted to assess relationships 
between genetic variants and TBI outcomes.  The BTRC typically enrolls 40 patients per year 
under their criteria for severe TBI.  With few exceptions (consent refused, patient or proxy 
unavailable to give consent) genetic consent was acquired on almost all patients who met the 
criteria.  Genetic data was obtained from blood or CSF samples in 336 patients.  
 
3.1.5 MitoChip Sampling 
 In the initial phase of the research, mitochondrial genotype data was collected using the 
MitoChip V2 array [120] in 136 patients.  The MitoChip V2 allows for genotyping of the entire 
16,569 base positions of the human mitochondrial genome.  The probes on the MitoChip match 
the revised Cambridge Reference Sequence (CRS) for human mtDNA, but also contain probes 
for the 500 most common mutations across haplotypes of the CRS as well [120]. Any position 
that was not monomorphic and had call rates above 95% from the MitoChip assays were 
included in the initial sample. There were a total of 19 mtDNA polymorphisms that met these 
criteria and were included in the primary sample: T146C, T195C, T477C, C3494T, T4216C, 
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A4917G, C7028T, A8701G, A10398G, A10550G, T10873C, A11947G, A12308G, C12705T, 
G13708A, T13789C, A14233G, C14766T, and T16519C. 
3.1.6 Additional Genotype Collection 
 In a preliminary analysis of mitochondrial variants and functional outcomes (Dr. Yvette 
Conley, personal discussion), four of the mtDNA variants (T195C, T4216C, A4917G, and 
A10398G) from the original sample of 136 had the strongest relationship to other TBI outcomes 
and were therefore collected in an additional 200 patients using Taqman® customized SNP 
assays (Applied Biosystems Inc., Carlsbad, CA) or RFLP techniques bringing the sample size for 
those four variants to 336, However, there were four subjects in which genotypes were unable to 
be collected using this method, so the total sample dropped to 332.  
 During the course of the univariate analysis for this study of the original 19 mtDNA 
variants in 136 individuals to PTS, two variants (T477C and T16519C), were found to have the 
strongest associations with LPTS.  The original cases were revaluated using Taqman® SNP 
assays to ensure accurate genotype call rates and additional samples for both variants were added 
to the analysis.  
 For each variant, the Wild Type (WT) genotype was taken from the most up to 
date Revised Cambridge Reference Sequence (rCRS) found on MitoMap.org (Last Access, July 
2012).  For this analysis WT = 0 and the Variant = 1.  Call rates for genotypes were above 90% 
for all the variants used in this analysis.  Each variant was examined among those who have 
EPTS and those who have LPTS. For the last two variants added to this analysis (T477C and 
T16519C), banked samples were no longer available for 38 cases, hence the smaller n’s for those 
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two variants compared to the others.  However, without those missing samples, the call rates for 
T477C and T16519 were at or above 90% and deemed acceptable for analysis. 
 
3.1.7 Power and Odds Ratio Estimates 
 As the sample size was fixed at 136 for 13 of the variants and 332 for 6 of the variants, 
estimates of power and effect sizes able to be detected were created using the PASS 11.0 (NCSS, 
Kaysville UT) software. A two proportion odds ratio (mtDNA variant present/absent vs. PTS 
Y/N) analysis was done to determine odds ratio and power for both the smaller and larger subsets 
of variants. 
 In the smaller subset (n=136) there were two variants in the 1-2% range, seven in the 3-
9% range and four in the 10-40% range for minor allele frequencies in this study.  For the 
variants with minor allele frequencies between 1-2%, odds ratios of 1.5, 2.0, and 3.0 were able to 
be detected with power between 2-3%.  For the variants with a minor allele frequency between 
3-9%, odds ratios of 1.5, 2.0 and 3.0 were able to be detected with power between 10-35%.  For 
those variants with minor allele frequencies between 10-40%, odds ratios of 1.5, 2.0 and 3.0 
were able to be detected with power between 15-70%. 
 In the larger subset (n=332) five of the variants had minor allele frequencies between 10-
35% and only one of the variants had a minor allele frequency of less than 10%.  For the one 
variant with a minor allele frequency of less than 10%, odds ratios of 1.5, 2.0 and 3.0 were able 
to be detected with power between 4-7%.  For those variants with minor allele frequencies 
between 10-35%, odds ratios of 1.5, 2.0 and 3.0 were able to be detected with power between 
10% and 85%. 
 53 
3.1.8 Genotyping 
Blood Samples: 
  
 Upon admission, a blood sample was collected in a 3-ml EDTA vacutainer tube and 
delivered to the genetics lab in the School of Nursing within 48 hours for DNA extraction. All 
samples were processed to remove the buffy coat and then stored in an -80ºC freezer in the 
School of Nursing laboratory until analyzed. All blood was drawn as per hospital policy using an 
existing arterial or central venous catheter 
CSF Samples: 
  
 CSF samples were collected every 12 hours for the first the first 5 days post-injury using 
passive drainage from a ventriculostomy placed by the neurosurgeon on call and verified by x-
ray as part of the standard of care.  The ventriculostomy bag was changed using sterile technique, 
and the CSF is removed from the collection system.  Three milliliters of CSF were aliquoted into 
a cryogenic tube, labeled with the date and time and identification number and stored in a -20C 
freezer.  After 5 days of samples were collected, the samples were transferred to -80ºC freezers 
in the School of Nursing for long-term storage.  Some mtDNA samples were obtained from this 
banked CSF for the current analysis. 
 
mtDNA Extraction: 
 
DNA was extracted from one of two sources for each subject, whole blood or CSF.  
Whole blood was collected in EDTA vacutainer tubes, processed to retrieve the buffy coat and 
DNA was extracted using a simple salting out procedure. CSF was collected by passive drainage 
as part of clinical care and DNA was extracted using the Qiamp DNA extraction protocol for 
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extraction from bodily fluids (Qiagen Corp, Valencia, California) [19]. DNA collection from 
whole blood was the preferred source when available. 
 
3.1.9 Demographic and Injury Data 
Demographic Data: 
  
Demographic information including age, sex, race, and ethnicity was recorded from 
medical records upon admission by the BTRC staff. Medical history; including a history of 
premorbid seizures, were recorded upon admission or from the patient’s medical records. 
Information regarding anti-seizure medication usage during the ICU and hospital stays was also 
extracted from medical records.  Each patient’s age was calculated in years using their date of 
birth from their records.  Length of hospital stay was calculated from the date of injury to their 
indicated discharge date in the medical records. 
  
Injury Data: 
  
The BTRC staff collected information on mechanism of injury (fall, motor vehicle 
accident, etc.). Injury severity (as defined by admission GCS score) was coded by the 
neurosurgeon responsible for clinical care of the BTRC after the patient was stabilized and not 
under the influence of any paralytic drugs. For this analysis GCS scores were categorized into 
the most severe group (i.e. GCS 3-4) and a less severe group (i.e. GCS 5-8). Injury data collected 
from the Trauma Registry included type of lesion (intracerebral hematoma, subdural hematoma, 
extradural hematoma, etc.) as indicated by the patients ICD 9 code in their medical record.   
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Evidence of depressed skull fractures and whether the patient had cranial surgery during their 
hospital stay were recorded. Some of the patients included in this analysis were previously 
enrolled in a larger prospective hypothermia trial within the BTRC.  Information on whether a 
person received cooling during their hospital stay was also abstracted from their medical records. 
 
Originally, it was planned to include data on injury location as evidenced by CT scan as 
one of the injury factors that may relate to PTS.  During the course of data collection and 
abstraction, it was found that the CT scan data was not consistently reported over time and 
different data collection methods made it difficult to choose which information to use.  The 
decision was made to use lesion types, mechanism, skull fracture, and cranial surgery as injury 
factors. 
 
3.1.10 Mortality 
Mortality data was collected using death reports from medical record or in the case of late 
occurring death from the social security death index. Deaths were coded as occurring during the 
first week, during the first month and during six months.  To avoid the confounding effects of 
death in this population of severe TBI, those who died in the first week without having seizure 
were excluded from analysis of EPTS.  If a subject had EPTS and then died, they were included 
in the analysis group.  To avoid the confounding effects of death in the LPTS group, anyone who 
died without evidence of seizure was removed from the analysis. 
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3.1.11 PTS Data 
To assess PTS activity, all electronic inpatient and outpatient medical records available 
were reviewed to document the first documented PTS. Time to first seizure in days was the 
primary measure abstracted from the medical records. Inpatient notes used to determine time to 
first seizure included ambulance emergency room reports, progress notes, nursing notes, EEG 
notes, patient history and physical reports and discharge or transfer summaries.  Determining late 
PTS required at least one discharge/death summary or inpatient/outpatient note related to the TBI 
and referencing the appropriate PTS time period.  Availability of late PTS information ranged 
from 6 months to 6 years post injury [19].  Time to first seizure was recorded in days from 
injury. PTS was coded into three different categories: early, late and delayed-onset.  EPTS were 
those that occurred between 1-7 days post injury, LPTS occurred after one week and before 6 
months, and delayed-onset seizures occurred after 6 months. Any premorbid history of seizures, 
and any information about the use of anti-epileptic drugs during the acute phase of the hospital 
stay was also abstracted from the electronic medical records. Information regarding additional 
seizures was not available. 
 For this analysis, due to the small sample sizes of the SNP data after adjusting for 
mortality in the population, the decision was made to condense the late and delayed-onset groups 
into a single group.  For this analysis, EPTS is considered to be any PTS activity that happens 
within the first week of injury and LPTS is considered to be any PTS that occurs beyond the 
seventh day post-injury.  This is in agreement with how EPTS and LPTS are considered in much 
of the PTS literature. 
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3.1.12 Functional Outcome Data 
 Different functional outcome variables were available via the BTRC database for most of 
the patients who were genotyped at a variety of time points. Glasgow Outcome Scale (GOS) data 
were available for many subjects at time periods of 6 and 12 months post-injury. The GOS is a 
clinical observation scale that categorizes functional outcomes into five levels: (1) Death, (2) 
Persistent vegetative state, (3) Severe disability, (4) Moderate disability, and (5) Good recovery. 
[121]. Interrater reliability has been reported from 68-95% [122]. GOS also correlates well with 
severity of injury and other measures of function such as the Disability Rating Scale [123].  The 
GOS has wide acceptance and established validity. Each outcome was reclassified into one of 
three groups; GOS 1=0, GOS 2-3=1, GOS 4-5=2.   In this analysis, since deaths were removed 
(see Figures below) there were essentially the two categories of GOS, with the first representing 
those with poor or severely impaired outcomes and the second with those who have better 
outcomes. 
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3.1.13 Study Inclusion: Smaller Subset 
 For 13 of the mitochondrial variants, 136 subjects met the inclusion criteria to be enrolled 
into the BTRC and had mtDNA genotyping done. To reduce the potential confounding effect of 
the existing seizure disorders on the development of PTS, 7 subjects with evidence of premorbid 
seizures were immediately excluded. 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Sample Selection - Smaller Subset of Populations (n=136) 
Removal of n=7 subjects with 
evidence of premorbid seizure. 
 
18 deaths with no 
evidence of PTS in 
first week removed.  1 
case with EPTS added 
back to analysis. 
Those with EPTS removed 
and all deaths without 
evidence of PTS removed. 
136 Subjects with Severe TBI who met Inclusion Criteria 
and had genotyping available 
129 Subjects Remaining 
103 No PTS 
9 with EPTS 
17 with LPTS 
112 Subjects Remaining 
103 No EPTS 
9 with EPTS 
79 Subjects Remaining 
62 No LPTS 
17 with LPTS 
 59 
3.1.14 Study Inclusion: Larger Subset 
 For 6 of the mitochondrial variants there were a total of 336 subjects who met the 
inclusion criteria for the BTRC and had mitochondrial genotyping done. 17 subjects with 
evidence of premorbid seizure were excluded from the final sample.  In addition, there were 3 
subjects in which no genotypes were able to be collected for any of the SNPs and they were 
excluded from the sample. The total sample size for the larger subset of data is 312.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Sample Selection – Larger Subset of Population (n=332) 
 
Removal of n=17 subjects with evidence 
of premorbid seizure or unknown status. 
Removal of n=3 subjects with no genotypes 
for any SNP. 
41 deaths in first week 
removed.  3 cases with 
EPTS before death 
added back to analysis. 
n=112 with EPTS and/or death without 
evidence of seizure removed. 1 case of 
LPTS before death added back to 
analysis.  
332 Subjects with Severe TBI who met Inclusion Criteria 
and had genotyping available. 
312 Subjects Remaining 
250 No PTS 
     21 with EPTS 
    41 with LPTS 
274 Subjects Remaining 
253 No  EPTS 
   21 with EPTS 
201 Subjects Remaining 
161 No LPTS 
40 with LPTS 
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3.2 ANALYSIS PLAN – AIM 1 
3.2.1 Specific Aim 1 
Examine the contribution of mtDNA variation to the development of both EPTS and 
LPTS in this cohort of severe TBI patients. 
3.2.2 Descriptive Variables 
 For descriptive purposes, measures of central tendency and dispersion will be obtained 
for all continuous variables at all available time points. Exploratory data analytic techniques and 
visual examination of trends and patterns will be utilized to become familiar with the data and to 
identify any potential outliers.  
3.2.3 Univariate Analysis 
 Chi-squared analysis of each mtDNA variant to compare allele frequencies between 
individuals who did and did not have EPTS and LPTS was performed. If any cell was too small 
for Chi-square analysis, Fisher’s exact tests were used.  The data were checked for excessive 
outliers and multiple missing values using visual inspection, as well as using the Data Validation 
and Missing Value Analysis functions in SPSS 20 (Chicago, IL). 
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3.2.4 Data Coding 
 Each of the 19 mtDNA genotypes in this analysis are coded such that the Wild Type = 0 
and the Variant =1.   
3.2.5 EPTS vs. mtDNA Variants 
 EPTS was coded as a binary variable in which 0 = no EPTS and 1 =EPTS.  When doing 
the analysis of variants vs. EPTS any subjects who died in the first week without evidence of 
seizure were excluded from the analysis.  There were 3 subjects with EPTS who later died in the 
first week. Since these subjects had evidence of EPTS before their death, they were added back 
into the analysis of the variants to EPTS.  In the smaller subset (n-136) – A total of 112 subjects 
were in the EPTS analysis.  In the larger subset (n=332) – A total of 274 subjects were in the 
EPTS analysis. 
3.2.6 LPTS vs. mtDNA Variants 
 LPTS was coded as a binary variable in which 0=no LPTS and 1 = LPTS. As the focus 
for this analysis was on subjects whose first seizure occurred after 7 days post-injury, any subject 
who had EPTS was removed from the analysis. Any subject who died without evidence of PTS 
was also removed from the analysis.  While this decreases the sample number, it eliminates the 
potential confounding effect of death.  In the smaller subset (n-136) – A total of 79 subjects were 
in the LPTS analysis.  In the larger subset (n=332) – A total of 201 subjects were in the LPTS 
analysis. 
 62 
3.2.7 Demographic and Injury Data vs. PTS 
 The majority of demographic and injury variables in this study were coded in a binary 
fashion.  Each of these factors was examined among individuals with and without EPTS/LPTS 
using Chi-squared tests or Fishers Exact test where appropriate to look for an association.  Age 
and Length of Hospital Stay were continuous variables and Independent samples t-tests were 
used to assess these variables for descriptive and comparative purposes. 
3.2.8 Multivariate Analysis 
To ensure that no potential associations between variants and the outcomes of EPTS or 
LPTS were being overlooked, any variant with a univariate test statistic of p<0.25 was entered 
into a binary logistic regression model. In the case of EPTS, there were a total of 4 variants that 
showed an association to EPTS in the Chi-Square analysis at this p-value level.  A series of 
models were built to test the individual effects of each variant on EPTS. Forward and backward 
stepwise procedures were used to assess which covariates assert influence in the model. An 
odds-ratio and 95% confidence interval was calculated for each variant that had a univariate 
association of p<0.25 in both the smaller and larger samples. 
 For each multivariate model, the clinical covariates of Gender, Age, and GCS were 
entered regardless of their significance in the univariate models as these are known covariates in 
the literature with both EPTS and LPTS.  Additionally, since SDH and Cranial Surgery 
associated strongly with LPTS in this analysis, these were added as additional covariates in the 
models of LPTS. 
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3.3 ANALYSIS PLAN – AIM 2 
3.3.1 Specific Aim 2 
Examine if selected injury factors associated with increased risk of both EPTS and LPTS, 
are affected by the presence of specific mtDNA variants in this cohort of severe TBI patients. 
3.3.2 Stratified Analysis of Injury Factor by LPTS by Variant 
To explore whether the mtDNA variants could potentially affect the relationship between 
injury factors and the outcome of LPTS, stratified analyses were done in which the injury factors 
that associated with LPTS at p<0.05 in the univariate analysis (SDH and Cranial Surgery) were 
compared to the outcome of LPTS, and each of the 19 mtDNA variants were then entered as 
stratifying variables.  This generated an odds ratio and significance for each allele with the injury 
factor of interest on the outcome of LPTS.   
In the next step, determination of which allele acted as the risk allele, the prevalence of 
each allele in those with LPTS (cases) was compared to the prevalence of the allele in those with 
no LPTS (controls).  For each variant, the risk allele was the one with a higher frequency in the 
cases than in the controls.  
In the final step to further explore whether there were any trends towards effect 
modification of mtDNA variants with the exposure variable (injury risk factors) on the outcome 
of PTS each of the variants was entered into a 2X4 table to assess their joint and individual 
effects on the outcome of LPTS (see figure 5 below).  The first row of table identifies the 
combined effect of the gene and exposure, the second row identifies the effect of the risk allele 
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alone, the third row identifies the effect of the exposure (I.e. the opposite allele and exposure) 
only, and the fourth row is the reference category.  The reference category is the control group 
(i.e. no risk allele and no exposure).  Odds ratios, confidence intervals, and p-values can be 
calculated for each combination of genetic factor and exposure allowing for direct comparisons 
between groups.  This model allows for risk estimates of gene environment interactions to be 
easily tested and visualized and allows for direct comparisons of the gene alone and exposure 
effect alone to be compared. It can also highlight issues related to small samples sizes, by 
providing confidence interval estimates for the risk estimates [124]. 
 
Strata Cases 
(Affected) 
Controls 
(Unaffected) 
Odds 
Ratio 
Information 
Gene & Exposure 
G+ E+ 
a b ah/bg Joint genotype and exposure 
factor compared to none. 
 
Gene & No Exposure 
G+ E- 
 
 
c 
 
d 
 
ch/dg 
 
Genotype alone vs. none 
No Gene & Exposure 
G- E+ 
 
e f eh/fg Exposure alone vs. none 
No Gene & No 
Exposure 
G- E- 
g h 1 Reference group  
Figure 5: Testing Gene-Environment Interactions 
Adapted from Botto et al., 2001[124] 
 
 65 
3.4 ANALYSIS PLAN – AIM 3 
3.4.1 Specific Aim 3 
To examine if EPTS and LPTS are associated with functional outcomes and if this 
relationship is affected by mtDNA variants in this population of severe TBI patients. 
 
3.4.2 Stratified Analysis of LPTS by GOS by Variant 
To determine is EPTS or LPTS was associated with worse functional outcomes at 6 
months post-injury, those with PTS were compared to those with worse outcomes (GOS 1-3) and 
those with better outcomes (GOS 4-5).  EPTS was not associated with GOS at 6 months, so the 
remainder of this analysis focuses on those with LPTS. Also, as deaths were removed from the 
LPTS group, the outcomes at 6 months became those alive with worse outcomes (GOS 2-3) 
compared to those alive with better outcomes (GOS 4-5). Those with and without LPTS were 
stratified by mtDNA variants to look for possible associations.  For the variants from the smaller 
subset (n=79), the cell sizes became too small to explore any further possible effect modification 
of the variant on outcome.  For this reason, the analysis in this section was restricted to the 
variants from the larger subset. During the initial stratification, the variant T477C had cells with 
no subjects so further stratification was unable to be performed.  During the initial stratification 
of the five remaining mitochondrial variants, and odds ratio and confidence interval was 
calculated for each variant.  
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In the next step, for each variant, the risk allele was the one with a higher frequency in 
the cases than in the controls. For further 2X4 analysis of LPTS to GOS, the determination of the 
risk allele for additional stratification was done by taking the prevalence of the allele in those 
with LPTS (cases) compared to the prevalence of the allele in those with no LPTS (controls).   
 In the final step, to explore possible trends of effect modification of the selected variants 
with the exposure (LPTS) on the outcome of GOS, they were entered into a 2X4 table to assess 
their joint and individual effects on the outcome of poorer GOS (see figure 5). Odds ratios, 
confidence intervals and p-values were computed for each row allowing for direct comparisons 
of allele & exposure, allele alone and exposure alone.  This model allows for risk estimates of 
gene exposure interactions to be easily tested and visualized and allows for direct comparisons of 
the gene alone and exposure effect alone to be compared. It can also highlight issues related to 
small samples sizes, by providing confidence interval estimates for the risk estimates [124]. 
3.4.3 Statistical Analysis Resources 
All primary statistical analyses were completed using SPSS version 20 (Chicago, IL) and 
additional online resources were used to aid in computation of Odds Ratios, confidence intervals 
and exact p-values for the 2X4 tables. 
EpiMax for Calculating OR’s and CI: http://www.healthstrategy.com/epiperl/epiperl.htm 
 
Exact p-value calculator for RXC tables: http://www.physics.csbsju.edu/cgi-bin/stats/exact 
 
Vassar p value calculator for RXC tables: http://vassarstats.net/newcs.html 
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4.0  RESULTS 
4.1 GENERAL POPULATION DESCRIPTION 
4.1.1 Description of Population 
Nineteen mitochondrial variants were analyzed initially in a total of 136 subjects and 6 
were analyzed in larger sample of 336. Descriptive analyses were done to compare the smaller 
subset (n=129) and larger subset (n=312) after removal of those with premorbid seizures and 
cases with no genotype information. No major differences were noted in any of the demographic, 
clinical, or injury characteristics between the two subsets (Tables 1 and 2). Since the original 136 
subjects were included in the larger subset, the following descriptions of the sample are based 
upon the entire population. 
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 Table 1: Population Characteristics in Large and Small Subests 
Variable n=312 
Count (%) 
 n=129 
Count (%) 
Gender 
Male 
Female 
 
 
245 (78.5) 
  67 (21.5)  
  
99 (76.7) 
30 (23.3) 
Race 
Caucasian 
African American 
Other/Biracial 
Missing 
 
288 (92.3) 
  18 (5.8) 
    3 (1.0) 
    2 (.6) 
  
121 (93.8) 
    7 (5.4) 
    1 (.8) 
     - 
 
Age 34.13+-14.72  35.02+-15.33 
 
Length of Stay 20.54+-11.93  21.63+-11.85 
 
AED 
Yes 
No 
Missing 
 
293 (93.9) 
  18 (5.8) 
    1 (.3) 
 
  
123 (95.3) 
    6 (4.7) 
Hypothermia 
Yes 
No 
 
  76 (24.4) 
236 (75.6) 
  
  20 (15.5) 
109 (84.5) 
 
GCS 
3-4 
5-8 
Missing 
 
  71 (22.8) 
232 (74.4) 
    9 (2.9) 
  
31 (24.0) 
97 (75.2) 
   1 (.8) 
Frequencies are after removal of those with premorbid seizure. 
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 Table 2: Injury Characteristics Large and Small Subsets 
VARIABLE N=312 
n (%) 
 N=129 
n (%) 
Mechanism 
Motor Vehicle 
Motorcycle 
Fall/ Sport 
Hit/Assault 
Other 
Missing 
 
191 (61.2) 
  47 (15.1) 
  57 (18.3) 
    8 (2.6) 
    5 (1.6) 
    4 (1.3) 
  
72 (55.8) 
24 (18.6) 
23 (17.8) 
  5 (3.9) 
  3 (2.3) 
  2 (1.6) 
ICD9 – SDH 
Yes 
No 
Missing 
 
170 (54.5) 
102 (32.7) 
  40 (12.8) 
  
78 (60.5) 
51 (39.5) 
 
ICD9 – SAH 
Yes 
No 
Missing 
 
183 (58.7) 
  89 (28.5) 
  40 (12.8) 
  
93 (72.1) 
36 (27.9) 
 
ICD9 – DAI 
Yes 
No 
Missing 
 
  86 (27.6) 
186 (59.6) 
  40 (12.8) 
 
 
 
  48 (37.2) 
  81 (62.8) 
 
ICD9 – EDH 
Yes 
No 
Missing 
 
  44 (14.1) 
228 (73.1) 
  40 (12.8) 
  
  16 (12.4) 
113 (87.6) 
ICD9 – CONTUSION 
Yes 
No 
Missing 
 
127 (40.7) 
145 (46.5) 
  40 (12.8) 
  
  61 (47.3) 
  68 (52.7) 
ICD9 – IVH 
Yes 
No 
Missing 
 
  81 (26.0) 
191 (61.2) 
  40 (12.8) 
  
  44 (34.1) 
  85 (65.9) 
ICD9 – ICH 
Yes 
No 
Missing 
 
  97 (31.1) 
175 (56.1) 
  40 (12.8) 
  
  40 (31.0) 
  89 (69.0) 
ICD9 – OTHER 
Yes 
No 
Missing 
 
  21 (6.7) 
251 (80.4) 
  40 (12.8) 
  
    7 (5.4) 
122 (94.6) 
SKULL FRACTURE 
Yes 
No 
Missing 
 
  15 (4.8) 
271 (86.9) 
  26 (8.3) 
  
    8 (6.2) 
107 (82.9) 
  14 (10.9) 
CRANIAL 
SURGERY 
Yes 
No 
Missing 
 
 
119 (38.1) 
167 (53.5) 
  26 (8.4) 
 
  
   
42 (32.6) 
  73 (56.6) 
  14 (10.9) 
Frequencies are after removal of those with premorbid seizure. 
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4.1.2 Demographic and Clinical Characteristics 
 The population is largely male (78.5%), Caucasian (92.3%) and relatively young (34 
years ±14).  The average inpatient stay was almost 21 days (20.54±12) and the vast majority of 
subjects (93.9%) were given anti-epileptic drugs during at least the first week of their hospital 
stay. All patients had initial GCS scores in the 3-8 range, further stratification of GCS into more 
severe (GCS 3-4) and less severe categories (GCS 5-8), shows that the majority (74.4%) fell into 
the range of GCS 5-8.  Some of the subjects from this sample were also enrolled in previous 
trials of induced hypothermia for TBI.  However, more than 75% of the subjects in this sample 
were part of the normothermic control groups.  
4.1.3 Race and Ethnicity 
 The vast majority of subjects were Caucasian (>92%) in both smaller and larger samples.  
While it is known that ancestral background can influence allele frequency, the MitoChip assay 
does account for the 500 most common SNPs from the major mtDNA haplogroups.  During the 
initial analysis of the variants vs. PTS status and the demographic and injury variables vs. PTS, 
all races were left in and a second scenario was created using only Caucasians.  In these samples, 
omitting race had no effect on any of the outcome measures, and due to the limited sample size 
of this study, it was decided to leave all races in the final analysis.  For ethnicity, there was a 
tremendous amount of nonresponses (>60%), and in those who did respond, over 99% reported 
as non-Hispanic so it was decided to not try and analyze based upon ethnicity. 
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4.1.4 Injury Characteristics 
Motor vehicle accidents were the primary mechanism of injury (61.2%), followed by 
injuries due to falls (18.3%), motorcycle accidents (15.1%), being hit by objects (2.6%) and 
other unidentified causes (1.6%).  It should be noted that in the smaller subset, injuries due to 
motorcycle accidents were slightly higher than in the larger subset.  
Injury types were classified according to the ICD 9 codes abstracted from the Trauma 
Registry.  The two most common injury categories were Subdural Hematoma (SDH) and 
Subarachnoid Hemorrhage (SAH).  When missing data was accounted for SAH was present in 
67% and SDH was present in 62.5% of the subjects. Skull fractures were present in only about 
5% of the subjects and cranial surgical procedures were performed on 41.6% of the subjects.   
 
4.1.5 Mortality 
 Mortality was above 32%, with approximately 13% of deaths occurring in the first week 
and 19% of deaths occurring after the first week.  None of the 19 variants were associated with 
increased mortality. 
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4.2 POPULATION DESCRIPTIONS FOR EPTS AND LPTS 
4.2.1 PTS Status 
As a preliminary analysis, each of the 19 mtDNA variants were compared initially to all 
PTS (i.e. PTS Y/N).  The overall frequency of PTS in both the smaller and larger subsets was 
approximately 26% after the removal of those with premorbid seizures and deaths without 
evidence of seizures.   There were no associations between the 19 variants and all PTS 
(Appendix C).  Subjects were then categorized into either EPTS or LPTS for the remainder of 
the study. 
 After adjustments were made for early mortality in the EPTS group, 8% had seizures 
during the first week after injury and 92% had no evidence of seizure.  In the LPTS group after 
adjustments were made to remove those who died and/or had evidence of early seizures, 19.9% 
had LPTS and 80.1% had no evidence of LPTS. In the first stage of the univariate analysis, 
EPTS and LPTS were examined to assess potential differences in demographic, clinical and 
injury covariates in the both the small and large subsets of the population. Demographic and 
injury comparisons for the smaller subset of the population are found in Tables 3 and 4. For the 
larger subset they are found in Tables 5 and 6. 
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Table 3: Demographic and Clinical vs. EPTS and LPTS in Smaller Subset 
Variable 
 
NO EPTS  
Count (%) 
n=112+ 
EPTS 
Count (%) 
n=112+ 
p-value*  NO LPTS 
Count (%) 
n=79# 
LPTS 
Count (%) 
n=79# 
p-value* 
Gender  
Male  
Female 
 
82 (91.1) 
21 (95.5) 
 
 
8 (8.9) 
1 (4.5) 
 
p=0.686 
  
50 (78.1) 
12 (80.0) 
 
14 (21.9) 
  3 (20.0) 
 
p=1.000 
Race 
Caucasian  
Black  
Other/Biracial  
 
 
97 (93.3) 
  5 (71.4) 
  1 (100.0) 
 
7 (6.7) 
2 (28.6) 
0 (0.0) 
 
p=0.172 
 
  
58 (77.3) 
  3 (100.0) 
  1 (100.0) 
 
17 (22.7) 
  0 (0.0) 
  0 (0.0) 
 
p=0.679 
 
AEDs in week 1 
Yes 
No 
 
 
99 (91.7) 
  4 (100.0) 
 
9 (8.3) 
0 (0.0) 
 
p=1.000 
  
60 (77.9) 
 2 (100.0) 
 
17 (22.1) 
0 (0.0) 
 
p=1.000 
Hypothermia 
Yes 
No 
 
 
17 (100.0) 
86 (90.5) 
 
0 (0.0) 
9 (9.50) 
 
p=0.350 
  
11 (73.3) 
51 (79.7) 
 
  4 (26.7) 
13 (20.3) 
 
p=0.728 
Age 
years 
 
 
34.36±15.0 
 
 
34.89±14.5 
 
 
p=0.919 
 
  
30.76±12.6 
 
 
30.65±11.6 
 
p=0.974 
 
LOSH 
Days 
 
 
24.04±10.6 
 
 
21.67±14.1 
 
 
p=0.533 
 
  
24.54±10.4 
 
26.88±11.2 
 
p=0.421 
 
* - Chi-squared analysis, Fisher’s Exact test or independent samples t-test where appropriate. 
+ - Deaths with no evidence of seizure in the first week removed. 
# - Those with EPTS and/or death without evidence of seizure removed. 
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Table 4: Injury Variables vs. EPTS and LPTS in Smaller Subset 
Variable No EPTS 
Count (%) 
N=112+ 
EPTS 
Count (%) 
N=112+ 
p-value*  NO LPTS 
Count (%) 
n=79# 
LPTS 
Count (%) 
n=79# 
p-value*  
 
GCS 
3-4  
5-8 
 
 
24 (96.0) 
79 (90.8) 
 
1 (4.0) 
8 (9.2) 
 
p=0.470 
 
  
11 (73.3) 
51 (79.7) 
 
  4 (26.7) 
13 (20.3) 
 
p=0.728 
 
MECHANISM 
Motor Vehicle 
Motorcycle 
Fall/Sport 
Hit By/Assault 
Other 
 
 63 (96.9) 
 18 (78.3) 
 14 (93.3) 
   4 (80.0) 
   3 (100.0) 
 
2 (3.1) 
5 (21.7) 
1 (6.7) 
1 (20.0) 
1 (0.0) 
 
 
p=0.062 
 
  
42 (82.4) 
  9 (69.2) 
  5 (71.4) 
  3 (75.0) 
  3 (100.0) 
 
9 (17.6) 
4 (30.8) 
2 (28.6) 
1 (25.0) 
0 (0.0) 
 
p=0.738 
ICD9 – SDH 
Yes 
No 
 
 61 (89.7) 
 42 (95.5) 
 
7 (10.3) 
2 (4.5) 
 
p=0.318 
  
33 (75.0) 
29 (82.9) 
 
11(25.0) 
 6 (17.1) 
 
p=0.399 
ICD9 – SAH 
Yes 
No 
 
 72 (93.5) 
 31 (88.6) 
 
5 (6.5) 
4 (11.4) 
 
p=0.457 
  
40 (81.6) 
22 (73.3) 
 
9 (18.4) 
8 (26.7) 
 
p=0.384 
ICD9 – DAI 
Yes 
No 
 
43 (93.5) 
60 (90.9) 
 
3 (6.5) 
6 (9.1) 
 
p=0.735 
  
27 (87.1) 
35 (72.9) 
 
  4 (12.9) 
13 (27.1) 
 
p=0.134 
ICD9 – EDH 
Yes 
No 
 
15 (100.0) 
88 (90.7) 
 
0 (0.0) 
9 (9.3) 
 
p=0.360 
  
12 (85.7) 
 50(76.9) 
 
  2 (14.3) 
15 (23.1) 
 
p=0.517 
ICD9 –Contusion 
Yes 
No 
 
44 (91.7) 
59 (92.2) 
 
4 (8.3) 
5 (7.8) 
 
p=1.000 
  
26 (78.8) 
36 (78.3) 
 
  7 (21.2) 
10 (21.7) 
 
p=0.955 
ICD9 – IVH 
Yes 
No 
 
33 (91.7) 
70 (92.1) 
 
3 (8.3) 
6 (7.9) 
 
p=1.000 
  
19 (82.6) 
43 (76.8) 
 
  4 (17.4) 
13 (23.3) 
 
p=0.765 
ICD9 – ICH 
Yes 
No 
 
33 (91.7) 
70 (92.1) 
 
3 (8.3) 
6 (7.9) 
 
p=1.000 
  
20 (80.0) 
42 (77.8) 
 
  5 (20.0) 
12 (22.2) 
 
p=0.823 
ICD9 – Other 
Yes 
No 
 
    3 (100.0) 
100 (91.7) 
 
0 (0.0) 
9 (8.3) 
 
p=1.000 
 
  
  1 (100.0) 
61 (78.2) 
 
  0 (0.0) 
17 (21.5) 
 
p=1.000 
Skull Fx 
Yes  
No 
 
  7 (100.0) 
87 (93.5) 
 
0 (0.0) 
6 (6.5) 
 
p=1.000 
  
  5 (83.3) 
51 (76.1) 
 
  1 (16.7) 
16 (23.9) 
 
p=1.000 
 
Cranial Surgery 
Yes 
No 
 
35 (92.1) 
59 (95.2) 
 
3 (7.9) 
3 (4.8) 
 
p=0.671 
 
  
15 (53.6) 
41 (91.1) 
 
13 (46.4) 
  4 (8.9) 
 
p=0.000 
* - Chi-squared analysis, Fisher’s Exact test and independent samples t-test where appropriate. 
+ - Deaths with no evidence of seizure in the first week removed. 
# - Those with EPTS and/or death without evidence of seizure removed. 
Bold values in the table indicate a significant test statistic (p<0.05). 
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Table 5: Demographic and Clinical vs. EPTS and LPTS in Larger Subset 
Variable 
 
NO EPTS  
Count (%) 
n=274+ 
EPTS 
Count (%) 
n=274 
p-value*  NO LPTS 
Count (%) 
n=201# 
LPTS 
Count (%) 
n=201 
p-value* 
Gender  
Male  
Female 
 
200 (91.7) 
  53 (94.6) 
 
 
18 (8.3) 
  3 (5.4) 
 
p=0.583 
  
125 (80.1) 
  36 (80.0) 
 
31 (19.9) 
  9 (20.0) 
 
p=0.985 
Race 
Caucasian  
Black  
Other/Biracial  
 
 
234 (92.9) 
  14 (82.4) 
    3 (100.0) 
 
18 (7.1) 
  3 (17.6) 
  0 (0.0) 
 
p=0.322 
 
  
146 (78.9) 
  12 (100.0) 
    1 (50.0) 
 
39 (21.1) 
  0 (0.0) 
  1 (50.0) 
 
p=0.092 
 
AEDs in week 1 
Yes 
No 
 
 
241 (92.0) 
  12 (100.0) 
 
21 (8.0) 
  0 (0.0) 
 
p=0.608 
  
151 (79.1) 
  10 (100.0) 
 
40 (20.9) 
0 (0.0) 
 
p=0.216 
Hypothermia 
Yes 
No 
 
 
  67 (98.5) 
186 (90.3) 
 
  1 (1.5) 
20 (9.7) 
 
p=0.027 
  
  42 (77.8) 
119 (81.0) 
 
12 (22.2) 
28 (19.0) 
 
p=0.617 
Age 
years 
 
 
32.94±14.0 
 
 
36.14±15.5 
 
 
p=0.317 
 
  
30.22±12.2 
 
 
31.10±10.9 
 
p=0.677 
 
LOSH 
Days 
 
 
22.76±10.8 
 
 
21.43±13.2 
 
 
p=0.593 
 
  
22.66±10.4 
 
25.30±12.6 
 
p=0.171 
 
* - Chi-squared analysis, Fisher’s Exact test and independent samples t-test where appropriate. 
+ - Deaths with no evidence of seizure in the first week removed. 
# - Those with EPTS and/or death without evidence of seizure removed. 
Bold values in the table indicate a significant test statistic (p<0.05). 
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Table 6: Injury Variables vs. EPTS AND LPTS in Larger Subset 
Variable No EPTS 
Count (%) 
N=274+ 
EPTS 
Count (%) 
N=274+ 
p-value*  NO LPTS 
Count (%) 
n=201# 
LPTS 
Count (%) 
n=201# 
p-value*  
 
GCS 
3-4  
5-8 
 
 
  53 (96.4) 
194 (91.1) 
 
  2 (3.6) 
19 (8.9) 
 
p=0.265 
 
  
  25 (75.8) 
131 (80.4) 
 
  8 (24.2) 
32 (19.6) 
 
p=0.549 
 
MECHANISM 
Motor Vehicle 
Motorcycle 
Fall/Sport 
Hit By/Assault 
Other 
Missing 
 
 
167 (94.9) 
  37 (86.0) 
  35 (87.5) 
    6 (85.7) 
    5 (100.0) 
    3 (100.0) 
 
  9 (5.1) 
  6 (14.0) 
  5 (12.5) 
  1 (14.3) 
  0 (0.0) 
  0 (0.0) 
 
p=0.231 
 
  
113 (82.5) 
  23 (74.2) 
  17 (85.0) 
    4 (66.7) 
    3 (75.0) 
    1 (33.3) 
 
24 (17.5) 
  8 (25.8) 
  3 (15.0) 
  2 (33.3) 
  1 (25.0) 
  2 (66.7) 
 
p=0.256 
ICD9 – SDH 
Yes 
No 
 
130 (89.0) 
  85 (94.4) 
 
 16 (11.0) 
   5 (5.6) 
 
p=0.157 
  
72 (72.7) 
66 (90.4) 
 
27(27.3) 
 7 (9.6) 
 
p=0.004 
ICD9 – SAH 
Yes 
No 
 
 136 (90.1) 
   79 (92.9) 
 
15 (9.9) 
  6 (7.1) 
 
p=0.456 
  
81 (78.6) 
57 (82.6) 
 
22 (21.4) 
12 (17.4) 
 
p=0.522 
ICD9 – DAI 
Yes 
No 
 
  76 (93.8) 
139 (89.7) 
 
  5 (6.2) 
16 (10.3) 
 
p=0.288 
  
52 (85.2) 
86 (77.5) 
 
  9 (14.8) 
25 (22.5) 
 
p=0.238 
ICD9 – EDH 
Yes 
No 
 
  36 (90.0) 
179 (91.3) 
 
  4 (10.0) 
17 (8.7) 
 
p=1.000 
  
  23 (71.9) 
115 (82.1) 
 
  9 (28.1) 
25 (17.9) 
 
p=0.188 
ICD9 –Contusion 
Yes 
No 
 
  95 (90.5) 
120 (91.6) 
 
10 (9.5) 
11 (8.4) 
 
p=0.763 
  
60 (82.2) 
78 (78.8) 
 
13 (17.8) 
21 (21.2) 
 
p=0.580 
ICD9 – IVH 
Yes 
No 
 
  66 (91.7) 
149 (90.9) 
 
  6 (8.3) 
15 (9.1) 
 
p=0.840 
  
  38 (79.2) 
100 (80.6) 
 
10 (20.8) 
24 (19.4) 
 
p=0.827 
ICD9 – ICH 
Yes 
No 
 
  75 (89.3) 
140 (92.1) 
 
  9 (10.7) 
12 (7.9) 
 
p=0.466 
  
46 (80.7) 
92 (80.0) 
 
11 (19.3) 
23 (20.0) 
 
p=0.913 
ICD9 – Other 
Yes 
No 
 
 
  12 (80.0) 
203 (91.9) 
 
  3 (20.0) 
18 (8.1) 
 
p=0.137 
 
  
    7 (87.5) 
131 (79.9) 
 
  1 (12.5) 
33 (20.1) 
 
p=0.701 
Skull Fx 
Yes  
No 
 
  14 (100.0) 
221 (92.9) 
 
  0 (0.0) 
17 (7.1) 
 
p=0.608 
  
   8  (80.0) 
139 (78.5) 
 
  2 (20.0) 
38 (21.5) 
 
p=1.000 
 
Cranial Surgery 
Yes 
No 
 
  96 (91.4) 
139 (94.6) 
 
9 (8.6) 
8 (5.4) 
 
p=0.329 
 
  
48 (63.2) 
99 (89.2) 
 
28 (36.8) 
12 (10.8) 
 
p=0.000 
* - Chi-squared analysis, Fisher’s Exact test and independent samples t-test where appropriate. 
+ - Deaths with no evidence of seizure in the first week removed. 
# - Those with EPTS and/or death without evidence of seizure removed. 
Bold values in the table indicate a significant test statistic (p<0.05). 
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4.2.2 Demographic and Clinical Associations with EPTS 
 Gender was not significantly associated with EPTS, but men were about one and half 
times (OR=1.59, .451-5.60) likely to develop EPTS than women in both the smaller and larger 
subsets of the population. Less than 15% of EPTS cases were races other than Caucasian.  
 Antiepileptic drug (AED) usage was considered in regards to EPTS. All of those with 
EPTS were also treated with AEDs during at least the first week after injury. Some of the 
subjects for this study were also enrolled in an earlier trial on hypothermia and TBI outcomes. 
Only 1 subject who received cooling developed EPTS (p=0.027).  Those with EPTS were 
slightly older than those without (36 vs. 33), but the difference was not significant (p=0.317).  
There was less than a one day difference (20 vs. 21) in the length of hospital stay between the 
EPTS and No EPTS groups. 
4.2.3 Injury Associations with EPTS 
Although GCS was not significantly associated with EPTS in either the smaller or larger 
subsets approximately 90% of those with EPTS fell into the less severe category compared to 
78% of those without EPTS. Mechanism of injury was not significantly associated with EPTS 
(p=0.231), but there appears to be a trend towards more injuries due to motorcycle and falls in 
the EPTS group.  In the smaller subset, motorcycle injuries were significantly associated 
(p=0.018) with EPTS when grouped vs. all other injury types.  A comparison of GCS scores to 
motorcycle injuries shows that 24% of those with motorcycle injury are in the lower GCS strata 
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(3-4) compared to 18% in the higher GCS strata (5-8).  This is not a significant association, but 
may lend credence to the idea that those with EPTS and motorcycle injury have more severe 
injuries than those with LPTS. 
None of the lesion types as evidenced by ICD9 codes were significantly associated with 
EPTS in either the smaller or larger subsets of the population.  The lesion type with the strongest 
association to EPTS was SDH (p=0.157). None of the EPTS subjects had skull fractures, and 
having a cranial surgical procedure did not associate (p=0.329) with the development of EPTS. 
4.2.4 Demographic and Clinical Associations with LPTS 
 There were no gender differences between those with LPTS and those without (p=0.985). 
The slight gender difference between males and females found in the EPTS group were not 
observed in the LPTS group. At first glance, race appears to trend toward significance, but 
greater than 95% of those with LPTS were Caucasian in the larger subset and all of those in the 
smaller subset were Caucasian.  
AED usage was considered in regards to LPTS. All of the subjects with LPTS were 
treated with AEDs during at least the first week post-injury.   While more of those with LPTS 
were also included in the earlier hypothermia trials, there was no association between being 
cooled and LPTS (p=0.617). Those with LPTS were slightly older than those without (31 vs. 30), 
but the difference was not significant (p=0.677).  While direct univariate comparisons were not 
made, those with LPTS were almost 5 years younger than those with EPTS.  Those with LPTS 
had an average stay of approximately 26 days compared to 23 days in those without LPTS. 
However, the difference was not significant (p=0.171).  Those with LPTS generally had longer 
hospital stays than those with EPTS as well. 
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4.2.5 Injury Associations with LPTS 
Having a cranial surgical procedure is strongly associated with the development of LPTS 
(p=0.000) in both the smaller and larger subsets of the population.  Those who had cranial 
surgery were almost 5 times more likely to develop LPTS (OR=4.813, 2.25-10.28) compared to 
those who did not have any cranial surgeries. In the larger subset of cases, the injury lesion with 
the strongest association to LPTS was subdural hematoma (p=0.004). Those with a diagnosis of 
SDH were 3.5 times more likely to develop LPTS (OR=3.53, 1.44-8.66) than those without the 
diagnosis. Skull fractures did not associate with the development of LPTS (p=1.000) nor did any 
other lesion types in either the small or large subsets of the population. 
 
4.3 AIM 1 
4.3.1 mtDNA Variants and EPTS 
In the univariate analysis no variant was significantly associated with EPTS or LPTS in 
either the smaller subset that included 13 variants or the larger subset that contained 6 variants 
(see Table 7). Originally it was planned that any variant with a significant (p<0.05) association to 
either EPTS or LPTS would be entered into a binary logistic regression model with the most 
common demographic and clinical covariates that have been used in this population in previous 
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reports.  The multivariate model that is typically built includes gender, age and GCS as 
covariates regardless of their univariate significance.   Since no variants associated at p<0.05, it 
was decided to construct the same models using all 19 variants paying particular attention to 
those variants that had at least a marginal association with EPTS  (p<0.250) in the univariate 
analysis to ensure that no potential associations are being overlooked in the data.  The number of 
covariates entered into the models is deliberately kept small due to the overall small number of 
cases of EPTS and LPTS, particularly in the smaller subset. 
In the smaller subset, four variants were associated with EPTS at p<0.250.  C3494T 
(p=0.080), A8701G (p=0.084), A10550G (p=0.215) and T10873C (p=0.154) all showed some 
association with EPTS.  As seen in Table 7, for most variants there were very few cells that were 
positive for the variant and EPTS. T146C, A11947G, G13708A, and T13789A had no cases of 
EPTS and the variant of interest.  Additionally, T477C, C3494T, and A14233G each only had 
one case of that was positive for variant and EPTS.  These extremely small numbers present 
difficulties when trying to analyze any multivariate models or perform any stratified analyses.  
4.3.2 mtDNA Variants and LPTS 
Two variants associated with LPTS at p<0.250, one from the smaller subset (G13708A) 
and one from the larger subset (T16519C).  For G13708A (p=0.152) approximately 40% of those 
with the A allele had LPTS. For T16519C (p=0.053), approximately 25% of those with the T 
allele were in the LPTS group compared to only 12% with the C allele. While not significant, the 
odds of having the T allele and LPTS were more than 2 times greater than having the C allele 
and LPTS for T16519C. 
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As with the EPTS group there were very few cells that were positive for both the variant 
and LPTS. C3494T, T10873C, and T13789C had no cases of LPTS and the variant.  
Additionally, A8701G and A14233G each only had one case that was positive for the variant and 
LPTS.  These extremely small numbers present difficulties when trying to analyze any 
multivariate models or perform any stratified analyses in the LPTS group. 
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Table 7: mtDNA Variants vs. EPTS and LPTS 
¢ - mtDNA variants with additional samples. 
* - Chi-squared analysis and Fisher’s Exact test.  
+ - Deaths with no evidence of seizure in the first week removed. 
# - Those with EPTS and/or death without evidence of seizure removed. 
mtDNA  
Variant  
No EPTS + 
Count (%) 
EPTS+ 
Count (%) 
p-value* 
(n) 
 NO LPTS# 
Count (%) 
LPTS# 
Count (%) 
p-value* 
(n) 
T146C 
T 
C 
 
92 (91.1) 
11 (100.0) 
 
9 (8.9) 
0 (0.0) 
 
p=0.595 
(112) 
  
56 (78.9) 
  6 (75.0) 
 
15 (21.1) 
  2 (25.0) 
 
p=1.000 
(79) 
T195C ¢ 
T 
C 
 
193 (92.3) 
  49 (92.5)  
 
16 (7.7) 
  4 (7.5) 
 
p=1.000 
(262) 
  
123 (80.4) 
  29 (74.4) 
 
30 (19.6) 
10 (25.6) 
 
p=0.408 
(192) 
T477C ¢ 
T 
C 
 
202 (91.0) 
    9 (90.0) 
 
20 (9.0) 
  1 (10.0) 
 
p=1.000 
(232) 
  
130 (81.2) 
    6 (66.7) 
 
30 (18.8) 
  5 (33.3) 
 
p=0.380 
(171) 
C3494T 
C 
T 
 
103 (92.8) 
    0 (0.0) 
 
8 (7.2) 
1 (100.0) 
 
p=0.080 
(112) 
  
62 (78.5) 
  0 (0.0) 
 
17 (100.0) 
   0 (0.0) 
 
----------- 
(79) 
T4126C¢ 
T 
C 
 
193 (91.9) 
  59 (93.7) 
 
17 (8.1) 
  4 (6.3) 
 
p=0.792 
(273) 
  
121 (79.6) 
  39 (81.2) 
 
31 (20.4) 
  9 (18.8) 
 
p=0.804 
(200) 
A4917G¢ 
A 
G 
 
227 (92.7) 
  26 (89.7) 
 
18 (7.3) 
  3 (10.3) 
 
p=0.709 
(274) 
  
147 (80.8) 
14 (73.7) 
 
35 (19.2) 
  5 (26.3) 
 
p=0.545 
(201) 
C7028T 
C 
T 
 
40 (95.2) 
63 (90.0) 
 
2 (4.8) 
7 (10.0) 
 
p=0.480 
(112) 
  
21 (75.0) 
41 (80.4) 
 
  7 (25.0) 
10 (19.6) 
 
p=0.577 
(79) 
A8701G 
A 
G 
 
92 (93.9) 
11 (78.6) 
 
6 (6.1) 
3 (21.4) 
 
p=0.084 
(112) 
  
55 (77.5) 
  7 (87.5) 
 
16 (22.5) 
  1 (12.5) 
 
p=0.680 
(79) 
A10398G¢ 
A 
G 
 
176 (92.6) 
  50 (87.7) 
 
14 (7.4) 
  7 (12.3) 
 
p=0.279 
(247) 
  
110 (79.1) 
  34 (79.1) 
 
29 (20.9) 
  9 (20.9) 
 
p=0.992 
(182) 
A10550G 
A 
G 
 
94 (93.1) 
  9 (81.8) 
 
7 (6.9) 
2 (18.2) 
 
p=0.215 
(112) 
  
57 (79.2) 
  5 (71.4) 
 
15 (20.8) 
  2 (28.6) 
 
p=1.000 
(79) 
T10873C 
T 
C 
 
96 (93.2) 
  7 (77.8) 
 
7 (6.8) 
2 (22.2) 
 
p=0.154 
(112) 
  
58 (77.3) 
4 (100.0) 
 
17 (2.7) 
0 (0.0) 
 
p=0.572 
(79) 
A11947G 
A 
G 
 
100 (91.7) 
   3 (100.0) 
 
9 (8.3) 
0 (0.0) 
 
p=1.000 
(112) 
  
59 (77.6) 
  3 (100.0) 
 
17 (22.4) 
  0 (0.0) 
 
p=0.593 
(79) 
A12308G 
A 
G 
 
77 (92.8) 
26 (89.7) 
 
6 (7.2) 
3 (10.3) 
 
p=0.693 
(112) 
  
45 (77.6) 
17 (81.0) 
 
13 (22.4) 
  4 (19.0) 
 
p=0.773 
(79) 
C12705T 
C 
T 
 
90 (92.8) 
13 (86.7) 
 
7 (7.2) 
2 (13.3) 
 
p=0.605 
(112) 
  
53 (77.9) 
  9 (81.8) 
 
15 (22.1) 
  2 (18.2) 
 
p=1.000 
(79) 
G13708A 
G 
A 
 
92 (91.1) 
9 (100.0) 
 
9 (8.9) 
0 (0.0)` 
 
p=0.608 
(112) 
  
57 (81.4) 
  4 (57.1) 
 
13 (18.6) 
  3 (42.9) 
 
p=0.152 
(79) 
T13789C 
T 
C 
 
100 (91.7) 
   2 (100.0) 
 
9 (8.3) 
0 (0.0) 
 
p=1.000 
  
59 (77.6) 
  2 (100.0) 
 
17 (16.6) 
  0 (0.0) 
 
p=1.000 
(79) 
A14233G 
A 
G 
 
96 (92.3) 
  7 (87.5) 
 
8 (7.7) 
1 (12.5) 
 
p=1.000 
(112) 
  
58 (78.4) 
  4 (80.0) 
 
16 (21.6) 
  1 (20.0) 
 
p=1.000 
(79) 
C14766T 
C 
T  
 
43 (93.5) 
59 (90.8) 
 
3 (6.5) 
6 (9.2) 
 
p=0.733 
(112) 
  
24 (77.4) 
38 (80.9) 
 
7 (22.6) 
9 (19.1) 
 
p=0.713 
(79) 
T16519C¢ 
T 
C 
 
129 (90.8) 
  74 (92.5) 
 
13 (9.2) 
  6 (7.5) 
 
p=0.672 
(222) 
  
77 (75.5) 
52 (88.1) 
 
25 (24.5) 
  7 (11.9) 
 
p=0.053 
(161) 
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4.3.3 Multivariate Models: EPTS 
Despite the limited cell sizes, each variant with a p<0.250 in the univariate analysis  was 
entered into a multivariate model with EPTS as the dependent variable and the variant, age, 
gender, and GCS entered as covariates.  Previous univariate analyses of variants by gender 
revealed possible associations for T195C, A8701G, T10873C, C12705T, and T13789C.  
Additionally, T4216C showed a possible association with GCS scores in a similar univariate 
analysis so particular attention was paid to this variant as well. 
Of the variants entered into the multivariate model that controlled for the effects of 
gender, age and GCS, only A8701G showed an association with EPTS (Table 8). With other 
clinical covariates included in the model, those with the G allele appear almost 6 times more 
likely to have EPTS.  To determine if this was a valid association, variables were added and 
removed in a stepwise fashion to determine if they changed the association between the SNP and 
EPTS.  Gender is the one clinical factor that drives the association between A8701G and EPTS. 
Removal of gender at any step of the model has the most impact on the relationship and caused 
the association to return to its borderline significance from the univariate analysis.  Addition and 
removal of other covariates has no impact on the association. To further explore the relationship 
between the SNP and gender, stratified analysis was performed and it was found that no women 
had the A variant and EPTS and only 1 woman had the G variant and EPTS.  The paucity of 
cases in the female subgroup appears to be what is driving the association seen in the 
multivariate model. 
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Table 8: Multivariate Model of A8701G vs. EPTS 
Variable Exp(B) 
OR 
 
95% CI 
p-value 
A8701G 
(Odds of G/A) 
 
5.994 1.076-33.395 0.041 
Gender 
(Odds of F) 
 
3.769 .368-39.284 .263 
GCS 
(Odds of Lower) 
 
2.160 .246-18.959 .487 
Age 1.012 .966-2.060 .616 
Bolded values significant at p<0.05 
 
 
4.3.4 Multivariate Models: LPTS 
For LPTS, each variant from the univariate tests with p<0.250 was entered into a 
multivariate model with LPTS as the dependent variable. In addition to common covariates of 
age, gender, and GCS, the presence of SDH and Cranial surgery were also entered as covariates 
because of their significance in the univariate models. Previous univariate analyses of variants by 
gender revealed possible gender associations for T195C, A8701G, T10873C, C12705T, and 
T13789C.  Additionally, T4216C showed a possible association with GCS scores in a similar 
univariate analysis so particular attention was paid to these variants as well.  Of the 19 variants 
entered into the multivariate model that controlled for the effects of Gender, Age, GCS, SDH and 
Cranial Surgery, none showed any potential associations with LPTS, although T16519C was of 
borderline significance (p=0.095).  
In the case of T16519C the presence of the T allele was approaching significance (p= 
0.053) in the univariate model, but when clinical and significant injury covariates were 
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accounted for in the multivariate model (Table 9) the slight association from the univariate 
model became less significant.  Removal of other covariates without significant associations to 
LPTS also had no effect on the relationship between T16519C and LPTS. 
Table 9: Multivariate model of T16519C vs. LPTS 
Variable OR 95% CI p-value 
T16519C 2.376 .860-6.568 .095 
Gender .798 .275-2.316 .678 
Age .983 .947-1.020 .359 
GCS .780 .209-2.914 .711 
Cranial Surgery 3.909 1.599-9.557 .003 
SDH 2.687 .991-7.281 .052 
    
Bolded values significant at p<0.05 
4.4 AIM 2 
4.4.1 Injury Factors in LPTS 
 In the initial univariate analysis of injury factors (mechanism, lesion type, cranial 
surgery), there were no significant associations between any of the factors and the development 
of EPTS.  However, in the LPTS group, having a subdural hematoma (SDH) was significantly 
associated with LPTS (p=0.004) as was having a cranial surgical procedure (p=0.000).  Those 
with SDH were almost 4 times more likely to have LPTS than those who didn’t (Table 10).  
Those who had a cranial surgery were almost 5 times more likely to have LPTS than those who 
didn’t (Table 11). These results are similar to what was shown in the multivariate model above 
(Table 9). 
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Table 10: SDH vs. LPTS 
Variable  No LPTS LPTS TOTAL p-value* OR (CI) 
NO SDH 
count 
%  
 
 
66 
90.4 
 
7 
9.6 
 
73 
 
 
0.004 
 
 
3.54 (1.44-8.66) 
SDH 
count 
% 
 
72 
72.7 
 
 
27 
27.3 
 
99 
  
 
TOTAL 138 34 172   
*Chi-square test of independence.  
 
Table 11: Cranial Surgery vs. LPTS 
Variable  No LPTS LPTS TOTAL p-value* OR (CI) 
NO SURGERY 
count 
% 
 
 
99 
89.2 
 
12 
10.8 
 
111 
 
0.004 
 
 
4.81 (2.25-10.28) 
SURGERY 
count 
% 
 
48 
63.2 
 
 
28 
36.8 
 
76 
  
 
TOTAL 138 34 172   
*Chi-square test of independence.  
 
4.4.2 SDH Stratified Analysis 
As there were no direct univariate associations between variants and the outcome of 
LPTS or with the injury factors of SDH and Cranial surgery (see Appendix D Table 1) a series of 
stratified analyses were done to highlight the possible effects of specific alleles in combination 
with injury factors on the outcome of LPTS.  The initial stratification consisted of the injury 
factor compared to the outcome of LPTS, and each of the 19 variants was entered as stratifying 
variables (see Appendix D Table 2).    This generated an odds ratio and significance for each 
allele with the injury factor of interest on the outcome of LPTS.  For SDH, of the 19 variants 
entered only the 6 with additional samples from the larger subset had enough cases to allow for 
 87 
further stratification (see Appendix D Tables 3-8). For the 2X4 analysis of SDH by LPTS, 
determination of the risk allele for additional stratification was done by taking the prevalence of 
the allele in those with LPTS (cases) compared to the prevalence of the allele in those with no 
LPTS (controls) (Table 12). 
Table 12: Risk Allele selection SDH by Variant by LPTS 
mtDNA  
Variants (n)  
Allele  - Cases 
    (%) – (count) 
Allele  - Controls 
    (%) – (count) 
T195C   (165) 
 
 
T:  76% - (26/34)  
C:  24% - (8/34) 
T:  79% - (104/131) 
C:  21% - (27/131)   
T477C   (167) 
 
 
T:  91% - (29/32) 
C:    9% - (3/32) 
T:  95% - (129/135) 
C:  4% -   (6/136) 
T4216C (171) 
 
 
T:  79% - (27/34) 
C:  21% - (7/34) 
T:  77% - (106/138) 
C:  23% - (32/138) 
A4917G (172) 
 
 
A:  91% - (31/34) 
G:   9% - (3/34) 
A:  90% - (124/138) 
G:  10% - (14/138) 
A10398G (165) 
 
 
A:  76% - (26/34) 
G:  24% - (8/34) 
A:  77% - (101/131)  
G:  23% - (30/131) 
T16519C (160) 
 
 
T:  81% - (25/31) 
C:  19% - (6/31) 
T:  60% - (77/129) 
C:  40% - (52/129) 
Risk alleles are bolded in the table. 
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4.4.3 Summary: SDH by Variant by LPTS 
 The 2X4 tables presented in this section are meant for descriptive purposes and to explore 
whether any of the mtDNA variants and injury variables may affect the outcome of LPTS. Many 
of the models are influenced by very small cell sizes, which are easily visualized. Trends do 
seem to appear and possible allele and exposure effects could be borne out with a larger sample 
of cases and controls. In general if the odds ratios for the first row (risk allele + exposure) and 
the third row (non risk allele + exposure) were both increased, compared to the reference group, 
then it can be assumed that the exposure variable is causing the increased risk.  T16519C showed 
the most likely trend towards a combined effect of the risk allele and SDH.  T16519C was also 
the variant that had the strongest univariate association with LPTS (p=0.053). Those with the T 
allele and SDH (row 1) have a 6 times greater odds of developing LPTS than those than in the 
reference group, while those with the C allele and SDH (row 3) only have a 2 times greater odds 
of LPTS compared to the reference group (Table 18).  In contrast, in A10398G, the combined 
risk of the G allele and SDH (row 1) is similar to those with the A allele and SDH (row 3) 
compared to the reference group, therefore, the exposure of SDH is most likely driving the 
association (Table 17). 
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Table 13: T195C 
Strata LPTS NO LPTS Odds Ratio p-value* 
C AND SDH 7 10 5.36 (1.25-23.75) 0.012 
C AND NO SDH 1 17 0.45 (.01-4.34) 0.668 
T AND SDH 20 58 2.64 (.90-8.07) 0.072 
T AND NO SDH 6 46 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
Table 14: T477C 
Strata LPTS NO LPTS Odds Ratio (CI) p-value* 
C AND SDH 2 5   4.2 (.45-34.71) 0.156 
C AND NO SDH 1 1 10.5 (.247-458.51) 0.189 
T AND SDH 23 66 3.66 (1.30-10.80) 0.006 
T AND NO SDH 6 63 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
Table 15: T4216C 
Strata LPTS NO LPTS Odds Ratio (CI) p-value* 
T AND SDH 24 54 1.67   (.45-6.68) 0.574 
T AND NO SDH 3 52 0.216 (.03-1.33) 0.067 
C AND SDH 3 17 0.661 (.095-4.38) 0.695 
C AND NO SDH 4 15 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
Table 16: A4917G 
Strata LPTS NO LPTS Odds Ratio (CI) p-value* 
A AND SDH 26 64  1.21   (.201-9.40) 1.00 
A AND NO SDH 5 60 0.250 (.033-1.33) 0.167 
G AND SDH 1 8 0.375 (.010-7.73) 0.577 
G AND NO SDH 2 6 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
Table 17: A10398G 
Strata LPTS NO LPTS Odds Ratio (CI) p-value* 
G AND SDH 6 14 4.11 (.922-18.89) 0.060 
G AND NO SDH 2 16  1.20 (.144-8.15) 1.000 
A AND SDH 21 53 3.80 (1.23-12.57) 0.013 
A AND NO SDH 5 48 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
Table 18: T16519C 
Strata LPTS NO LPTS Odds Ratio p-value 
T AND SDH 20 38  6.31 (1.24-43.07) 0.014 
T AND NO SDH 5 39 1.53 (.234-12.57) 1.000 
C AND SDH 4 28 1.71 (.237-14.96) 0.681 
C AND NO SDH 2 24 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 90 
4.4.4 Cranial Surgery Stratified Analysis 
A similar approach was taken to explore potential modifying effects of the variants with 
the presence of cranial surgery on the outcome of LPTS (see appendix D Table 9). For Cranial 
Surgery, of the 19 variants entered, only 5 of the variants with additional samples from the larger 
subset had enough cases to allow for further stratification (see Appendix D Tables 10-14). For 
the analysis of Cranial surgery by LPTS, determination of the risk allele for additional 
stratification was done by taking the prevalence of the allele in those with LPTS (cases) was 
compared to the prevalence of the allele in those with no LPTS (controls).  The results are 
presented in Table 19. 
Table 19: Risk Allele Selection Cranial Surgery by Variant by LPTS 
mtDNA  
Variants (n)  
Allele  - Cases 
    (%) – (count) 
Allele  - Controls 
    (%) – (count) 
T195C   (179) 
 
 
T:  76% - (30/40)  
C:  25% - (10/40) 
T:  83% - (115/139) 
C:  17% - (24/139)   
T4216C (187) 
 
 
T:  78% - (31/40) 
C:  23% - (9/40) 
T:  76% - (111/147) 
C:  25% - (36/147) 
A4917G (187) 
 
 
A:  88% - (35/40) 
G:  13% - (5/40) 
A:  90% - (133/147) 
G:  10% - (14/147) 
A10398G (170) 
 
 
A:  76% - (29/38) 
G:  24% - (9/38) 
A:  80% - (106/132)  
G:  20% - (26/132) 
T16519C (150) 
 
 
T:  78% - (25/32) 
C:  22% - (7/32) 
T:  61% - (72/118) 
C:  39% - (48/118) 
Risk alleles are bolded in table. 
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4.4.5 Summary: Cranial Surgery by Variant by LPTS 
As anticipated none of the 2X4 models were significant considering the main effects 
models were not significant for variant by Cranial Surgery or variant by PTS status.  Many of the 
models are influenced by very small cell sizes in either the cases or controls.  While it appears at 
first glance that the effect of the allele plus the presence of cranial surgery has an effect on the 
outcome of LPTS, a closer inspection shows that for all the variants selected, the presence of 
cranial surgery itself is likely to be what is driving the apparent associations. The odds ratio of 
the risk allele and cranial surgery (row 1) compared to the reference group is highly significant 
for all the models.  The odds of the other allele and cranial surgery (row 3) were also highly 
significant in all but T16519C (Tables 20-24). 
T16519C was the only allele from the initial analysis that was approaching significance 
with LPTS. The combination of the T allele and brain surgery (row 1) is greater than the 
reference group.  While the combination of the C allele and cranial surgery also increased the 
odds of developing LPTS, the effect is not significant compared to the reference group.   
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Table 20: T195C 
Strata LPTS NO LPTS Odds Ratio p-value* 
C AND SURGERY 8 7 9.02   (2.33-36.23) 0.000 
C AND NO SURGERY 2 17 0.929 (.128-5.209) 1.000 
T AND SURGERY 20 36 4.39   (1.73-11.30) 0.000 
T AND NO SURGERY 10 79 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
Table 21: T4216C 
Strata LPTS NO LPTS Odds Ratio p-value* 
T AND SURGERY 21 36 7.00 (1.38-47.69) 0.007 
T AND NO SURGERY 10 75 1.60 (.295-11.42) 0.729 
C AND SURGERY 7 12 7.00 (1.06-58.30) 0.024 
C AND NO SURGERY 2 24 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
 
Table 22: A4917G 
Strata LPTS NO LPTS Odds Ratio p-value* 
G AND SURGERY 4 2 15.82   (2.11-143.88) 0.003 
G AND NO SURGERY 1 12 0.659   (.029-5.81) 1.000 
A AND SURGERY 24 46 4.13     (1.74-9.92) 0.000 
A AND NO SURGERY 11 87 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
 
Table 23:A10398G 
Strata LPTS NO LPTS Odds Ratio p-value* 
G AND SURGERY 5 11 4.21 (.975-18.03) 0.048 
G AND NO SURGERY 1 12 2.47 (.539-10.81) 1.000 
A AND SURGERY 24 46  6.07 (2.25-16.83) 0.000 
A AND NO SURGERY 11 87 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
 
Table 24: T16519C 
Strata LPTS NO LPTS Odds Ratio p-value* 
T AND SURGERY 18 22  8.73 (2.06-42.63) 0.000 
T AND NO SURGERY 7 50 1.43 (.314-7.94) 0.737 
C AND SURGERY 4 14 3.05 (.482-20.45) 0.211 
C AND NO SURGERY 3 32 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
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4.5 AIM 3 
4.5.1 GOS at 6 months by PTS 
When EPTS was evaluated as potential risk factor for GOS, there were no significant 
associations between having EPTS and worse outcomes (p=1.000).  Since there were no main 
effect between EPTS and GOS it was decided that to add the mitochondrial variants would not 
be productive in further exploring whether the variants were effect modifiers (see Table 25). 
When LPTS was evaluated as a potential risk factors for GOS, there was a significant 
association between LPTS and worse outcomes (p=0.002).  Those with LPTS were almost 3 
times more likely to fall into the lower GOS categories than those without LPTS (Table 26). 
Therefore, for the stratified models, LPTS will be the exposure variable and the outcome of 
interest will be the GOS 2-3 category and the variants were included to look for trends towards 
effect modification. 
Table 25: EPTS vs. GOS at 6 months 
Variable GOS 2-3 GOS 4-5 TOTAL p-value* OR (CI) 
EPTS 
count 
exp 
 
8 
9.2 
 
6 
7.8 
 
14 
 
 
0.175 
 
1.14 (.35-3.89) 
NO EPTS 
count 
exp 
 
107 
105.8 
 
92 
90.2 
 
199 
 
  
TOTALS 115 98 213   
* Chi-square test of independence. 
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Table 26: LPTS vs. GOS at 6 months 
Variable GOS 2-3 GOS 4-5 TOTAL p-value* OR (CI) 
LPTS 
count 
exp 
 
27 
18.7 
 
10 
18.3 
 
37 
 
0.004 
 
3.33 (1.41-8.01) 
NO LPTS 
count 
exp 
 
64 
72.3 
 
79 
70.7 
 
143 
  
TOTALS 91 89 180   
* - Chi-square test of independence 
4.5.2 Stratified Analysis of LPTS by GOS 6 months by Variant 
Initially all 19 variants were entered into a stratified analysis of LPTS by GOS with the 
outcome of interest being the lower GOS group (GOS 2-3).  Those with and without LPTS were 
stratified by mtDNA variants to look for possible associations.  For the variants from the smaller 
subset (n=79), the cell sizes became too small to explore any further possible effect modification 
of the variant on outcome.  For this reason, the analysis in this section will be restricted to the 
variants from the larger subset. During the initial stratification (see Appendix E Tables 15-19), 
the variant T477C had multiple cells with no subjects so further stratification was unable to be 
performed.  The five remaining variants are shown below (Table 27). 
Table 27: Stratified analysis of LPTS by GOS 6 Months by Variant 
mtDNA Variants (n)+ OR (95% CI) p- value * 
T195C (172) T – 4.48 (1.21-16.68) 
C – 1.31 (0.16-10.56) 
0.025 
 
T4216C (179) T – 3.50 (0.92-13.32) 
C – 2.38 (0.38-14.70) 
0.035 
 
A4917G (180) A – 2.87 (0.87-9.41) 
G – 5.40 (0.44-66.67) 
0.033 
 
A10398G (163) A – 2.89 (0.86-9.75) 
G – 4.00 (0.40-39.83) 
0.030 
 
T16519C (142) T – 9.75 (1.19-79.81) 
C – 0.86 (0.073-10.18) 
0.018 
 
+ - Differing n’s due to missing cases in the GOS or Variant groups. 
* Chi-Square test of independence or Fisher’s exact test where appropriate. 
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4.5.3 Risk Allele Selection 
For further 2X4 analysis of LPTS to GOS, the determination of the risk allele for 
additional stratification was done by taking the prevalence of the allele in those with LPTS 
(cases) compared to the prevalence of the allele in those with no LPTS (controls).  The results 
are presented in Table 28. 
Table 28: Risk Allele Selection for LPTS by GOS at 6 Months 
mtDNA  
Variants (n)  
Allele  - Cases 
    (%) – (count) 
Allele  - Controls 
    (%) – (count) 
T195C   (172) 
 
 
T:  79% - (15/19)  
C:  21% - (4/19) 
T:  80% - (123/153) 
C:  20% - (30/153)   
T4216C (171) 
 
 
T:  68% - (13/19) 
C:  32% - (20/91) 
T:  78% - (125/160) 
C:  22% - (35/160) 
A4917G (180) 
 
 
A:  79% - (15/19) 
G:   21% -  (4/19) 
A:  91% - (147/161) 
G:  9% - (14/161) 
A10398G (165) 
 
 
A:  74% - (14/19) 
G:  26% - (5/19) 
A:  78% - (112/144)  
G:  22% - (32/144) 
T16519C (142) 
 
 
T:  79% - (11/14) 
C:  21% - (3/14) 
T:  62% - (79/128) 
C:  38% - (49/128) 
Risk alleles are bolded in table. 
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4.5.4 Summary: LPTS by GOS 6 months by Variant 
 The combination of the T allele and LPTS for T195C appears to increase the risk of a 
worse outcome (GOS 2-3) compared to those who have the C allele and LPTS (Table 29).  The 
combination of the T allele and LPTS in 16519C appears to increase the risk of a poorer outcome 
at 6 months as well (Table 33).  For A10398G, it appears the LPTS is driving the increases in the 
odds ratios in rows 1 and 3 (Table 32).  LPTS appears to be strongly affecting the odds ratios in 
T4216C (Table 30) and A4917G (Table 31) as well.  While this analysis descriptive in nature, it 
may bear out with increased genotype samples, that certain mtDNA variants interact with LPTS 
to increase the risk of poorer functional outcomes in severe TBI patients. 
Table 29: T195C 
Strata GOS 2-3 GOS 4-5 Odds Ratio p-value* 
C AND LPTS 2 2 1.12 (0.11-11.59) 1.000 
C AND NO LPTS 13 17 0.85 (0.36-2.06) 0.865 
T AND LPTS 12 3 4.48 (1.10-21.15) 0.033 
T AND NO LPTS 58 65 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
Table 30: T4216C 
Strata GOS 2-3 GOS 4-5 Odds Ratio p-value* 
C AND LPTS 4 2 2.10 (0.31-17.21) 0.662 
C AND NO LPTS 16 19 0.88 (0.39-2.00) 0.896 
T AND LPTS 10 3 3.50 (0.83-16.92) 0.101 
T AND NO LPTS 61 64 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
Table 31: A4917G 
Strata GOS 2-3 GOS 4-5 Odds Ratio p-value* 
G AND LPTS 3 1 3.13 (0.28-78.53) 0.602 
G AND NO LPTS 5 9 0.58 (0.16-2.01) 0.503 
A AND LPTS 11 4 2.86 (0.79-11.24) 0.127 
A AND NO LPTS 72 75 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
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Table 32: A10398G 
Strata GOS 2-3 GOS 4-5 Odds Ratio p-value* 
G AND LPTS 10 4 2.50 (0.55-12.06) 0.305 
G AND NO LPTS 52 60 0.87 (0.37-2.04) 0.876 
A AND LPTS 4 1 4.00 (0.34-103.67) 0.442 
A AND NO LPTS 16 16 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
 
Table 33: T16519C 
Strata GOS 2-3 GOS 4-5 Odds Ratio p-value 
T AND LPTS 10 1 17.22 (1.95-396.32) 0.004 
T AND NO LPTS 40 39 1.77 (0.89-2.23) 0.563 
C AND LPTS 1 2 .861 (0.03-13.57) 0.641 
C AND NO LPTS 18 31 1  
* - Chi-square test of independence or Fisher’s exact test where appropriate. 
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5.0  DISCUSSION 
5.1 GENERAL FINDINGS 
 PTS is a heterogeneous condition and it has been proposed to depend on variation in the 
injury type and severity as well as on the different genetic backgrounds, ages and genders of the 
patients [36, 37]. More recently, genetic studies have revealed that several nuclear genetic 
variants (APOE, A1AR, and GAD) may act as risk factors in the development of PTS [16-20]. 
 Over the past few decades, numerous variations in the mitochondrial genome have been 
identified that lead to disrupted energy production, oxidative stress, and homeostatic imbalance. 
Many mitochondrial disorders exhibit seizure phenotypes as part of their pathogenesis and 
mitochondrial variants have been implicated in contributing to both inherited and acquired forms 
of epilepsy. This finding is not unexpected, given that mitochondrial diseases often manifest in 
those tissues with the highest energy demands (i.e. brain or muscle). However, the role that 
altered mtDNA and the associated mitochondrial dysfunction play in acquired seizure disorders 
(i.e. PTS) remains to be explored [52].  
The goals of this study were to explore whether mtDNA variants act as potential risk 
factors of the clinical phenotypes of PTS. To examine if any of the variants may act as effect 
modifiers between injury factors and PTS and if mtDNA variants may modify the relationship 
between PTS and functional outcomes (GOS) at 6 months post-injury.  
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The overall frequency of EPTS in this population of severe TBI patients was found to be 
8% and LPTS was found to be 19.9% after adjustments were made for mortality.  These finding 
are in agreement with previous work done in this population [19, 20] and with other studies done 
on patients admitted for head trauma where EPTS frequencies range from 4-16% and LPTS 
frequencies range from 5-25% [33, 43, 45, 48, 84].  In many population based studies, EPTS is 
often a risk factor for the prediction of LPTS; however, as the primary measure of seizure in this 
study was time to first seizure, and not number of subsequent seizures, that temporal relationship 
was unable to be tested.  Some of the patients in this sample were enrolled as part of an earlier 
hypothermia trial as well and only one patient of the 68 (1.5%) who received cooling in the 
larger subset developed EPTS.  This is in agreement with earlier works done on PTS in this 
population [19, 20] and with recent work done on seizure prevention in an animal model [125].  
The vast majority of the patients (95%) in this sample were treated with anti-epileptic drugs 
during their acute stay. Antiepileptic drugs are often given prophylactically to PTS patients to 
prevent further secondary brain injury and possibly aid in improving their functional outcomes 
[5]. Chang and Lowenstein performed a meta-analysis of the evidence regarding antiepileptic 
therapy prophylaxis in patients with severe TBI by examining and grading prospective studies 
that compared PTS rates in patients receiving these medications compared to controls with 
severe TBI who did not receive the medications. Patients receiving phenytoin had a significantly 
lower risk of developing EPTS (RR=0.37, 0.18-0.74) compared to controls that either received 
placebo or no antiepileptic therapy.  AED’s did not seem to have the same effect on preventing 
LPTS in severe TBI patients compared to controls. (RR=1.05, 0.82-1.35)[81].  Even though it 
appears that anti-epileptics decrease the rate of early seizures it doesn’t appear that there is 
evidence that the prevention of early seizures affects mortality, morbidity, or the development of 
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LPTS[12]. Further work needs to be done to understand the underlying risk factors and 
mechanisms of PTS in order to develop therapies that could identify targets for slowing, stopping 
and more effectively treating seizures[11]. 
 In regards to LPTS, the two factors with the strongest associations were the presence of a 
subdural hematoma (p=0.004) and cranial surgery (p=0.000).  Cranial surgeries took place 
during the acute hospital stay and are most often done within the first few days after injury (Dr. 
Amy Wagner personal communication). These two injury related factors will be discussed in 
more detail below in regards to the mtDNA variants. 
5.2 MTDNA VARIANTS AND PTS 
 Overall, no significant univariate associations were found between the 19 mtDNA 
variants and the outcomes of EPTS or LPTS. Variant T477C highlights the issue of exploratory 
analysis.  In the initial sample of 136 subjects it had a strong association with LPTS in both 
univariate (p=0.038) and multivariate models adjusted for age, GCS, and gender (p=0.044), but 
with the addition of more individuals, the association disappeared.   
 In regards to EPTS only one variant showed a potential association and had enough cases 
to evaluate with a limited multivariate model.  The A8701G variant showed the strongest 
association with EPTS in the univariate analysis (p=0.084) so it was entered a multivariate model 
along with age, gender and GCS status. This model showed a significant effect compared to the 
univariate analysis (p=0.041). It appeared that those who carried the G allele at 8701 were almost 
6 times more likely to have EPTS than those without the G allele. In further analysis using a 2X4 
stratified table it was found that of the 9 cases of EPTS 8 were male and 1 was female, which 
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may seem abnormally high (88%), but the ratio of men to women in the No EPTS group was 
above 80% as well.  Additionally none of the women carried the A allele, which may explain 
stronger level of significance in the logistic model. While unable to draw definite conclusions 
from this small sample, it should be noted that the A to G transition in 8701 results in an amino 
acid substitution in the ATP6 gene that has been identified as altering mitochondrial matrix pH 
and intracellular calcium functions [126]. Also, in a recent case control study done in China, 
A8701G was found to associate in both univariate and multivariate models with a greater risk of 
sporadic hypertension [127]. Since this variant is known to cause an amino acid change and has 
been implicated in mitochondrial energy dynamics, it may warrant further consideration as a 
biologically plausible candidate in future studies.  
 Of all the variants examined, T16519C had the strongest association with the outcome of 
LPTS (p=0.053) in the initial analysis and after the inclusion of additional genotyped individuals.  
The T allele appears to be the risk allele as over 70% of those with LPTS carried this allele 
compared to the C allele.  The odds of having the T allele and LPTS were about two times 
greater (2.07, 0.95-4.48) than having the C allele. When a multivariate model was created that 
adjusted for the most relevant clinical covariates and injury associations and the association 
between the T allele and LPTS was weakened somewhat (OR=2.38, 0.86-6.57, p=0.095).  While 
adjustments for other covariates lowered the association of T16519C to LPTS, some of this may 
be due the relatively small sample size.  In a larger sample T16519C may provide some 
information about the overall risk of developing LPTS.    
 T16519C has been reported as one of the most frequent variants across haplogroups 
worldwide [128] and is located in the D-loop region of the mitochondrial genome, The D-loop 
doesn’t code for any of the mitochondrial complex proteins or t-RNA’s needed for their 
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assembly, although some regions of the D-loop are thought to control and regulate transcription 
and replication of the mitochondrial genome. However, no reports in the literature were found 
that this variant is directly associated with that process. Higher frequencies of D-loop mutations 
(including T16519C) have been reported in tumor cells and it has been speculated that this might 
reflect increased oxidative damage in diseased cells compared to healthy cells [129].  
 A review of the literature relevant to T16519C found associations of both the T allele and 
C allele as possible markers for clinical conditions. T6519C has been associated with a higher 
risk of being on chronic dialysis [130], migraine headaches and cyclic vomiting syndrome [131], 
increased oxygen consumption during exercise [132] and nominal associations have been found 
linking bipolar and schizophrenia to mutations in T6519C and T195C [133]. There seems to be a 
building trend toward associations of this variant with clinical conditions and diseases involving 
high energy consumption tissues. While not a direct causative link to LPTS, further analysis of 
the role of T16519C and other D-loop variants may prove useful information regarding the long-
term outcomes after TBI. 
 The second aim of this study was to explore whether mtDNA variants acted as effect 
modifiers on the relationship between injury factors and the outcome of PTS. While no other 
studies exist of how mtDNA variants may act as effect modifiers on the phenotype of TBI, the 
concept of a variant acting to modify a phenotype is not unusual in the literature.  For example, 
Warfarin is prescribed to prevent blood clotting and prevent strokes, but patients vary widely in 
how much initial dose they need.  Warfarin dosing is correlated with relatively common SNPs in 
the VKORC1 and CYP2C9 nuclear genes that are thought to account for 30-40% of the 
variability seen in a patient’s response to the drug[134, 135].   
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 However, as there were no direct associations between the mtDNA variants and the 
outcome of LPTS; the original intent of testing whether the variants were moderators of the 
relationship between injury factors and the outcome of LPTS had to be reconsidered given the 
constraints of the data. The intent was to describe whether any trends exist that might be 
validated in larger, prospective studies. The injury factors that associate with PTS will be 
discussed first and then the process undertaken to try and describe how mtDNA variants might 
impact the relationship between those factors and PTS will be described. 
 Injury severity is a consistently documented risk factor for both EPTS and LPTS with 
those falling in the GCS 3-8 category having the highest risk of seizures [9, 32, 38]. Since all of 
the subjects in this study were severe TBI patients, it is not unexpected that GCS did not 
associate with PTS.  Multiple lesion types have been associated with both EPTS and LPTS in 
previous works, including intracerebral hematoma (ICH), subdural hematoma (SDH) and cortical 
contusions [32, 43]. Cranial surgery and the presence of depressed skull fractures (especially in 
penetrating head injuries) have also been consistently associated with the development of EPTS 
and LPTS [32, 33].  In this analysis, none of the commonly reported injury risk factors were 
significantly associated with the development of EPTS, although, there does seem to be a trend 
towards more injuries from motorcycle accidents and falls in this group compared to the LPTS 
group.  In the LPTS group the two factors with the strongest univariate associations were SDH 
(p=0.004) and cranial surgery (p=0.000).  
 For both SDH and cranial surgery, the 6 variants with enough cases to evaluate were 
entered into a 2X4 stratified analysis (see Tables 13-18 and 20-24) to explore for possible 
modifying effects of the variants on the outcome of LPTS. The only variant to show a strong 
trend towards increasing the outcome of LPTS in regards to both SDH and cranial surgery was 
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the T allele of T16519C, which is not unexpected since it had the highest univariate association 
with LPTS as well. These findings are also in line with the results of the multivariate model in 
which both SDH and cranial surgery were adjusted for and the risk of LPTS was still elevated for 
the T allele of 16519.  The trends shown here suggest that T16519C may play some role in 
conjunction with injury or clinical factors in modifying the outcome of LPTS.  
In the final part of this analysis, possible trends linking mtDNA variants and the 
phenotypes of PTS to functional outcomes were explored. In the univariate analysis of LPTS to 
GOS, it was found that those with LPTS had a greater likelihood (OR=3.33, 1.41-8.01) of having 
a poorer outcome at 6 months post-injury.  This is in agreement with much of the PTS literature. 
For example, LPTS has been associated with poorer GOS scores and higher incidence of 
behavioral abnormality in patients with severe TBI in India [46], and has also been associated 
with a higher incidence of depression [47]. A 5 year prospective study of rehabilitation and 
reemployment in Finland showed that LPTS was associated with poorer functional and social 
outcomes and was a considerable factor in hospital readmission [48]. Overall, it appears that PTS 
can result in greater psychiatric problems as well as reduced general health and poorer functional 
and social outcomes [12]. 
The 5 variants with enough cases to evaluate were entered into a 2X4 stratified analysis 
(see Tables 29-33) to explore for possible modifying trends of the variants on the outcome of 
LPTS.  Overall, it appears that T16519C and T195C have the strongest trends towards lower 
functional outcomes in those with LPTS.  
While unclear what the exact mechanism may be for the role of T16519C, it does lie very 
close to the beginning of the control region of the mtDNA (bp16160-570) in the D-loop region, 
which helps to control mitochondrial transcription and replication and multiple mutations in 
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control regions variants (T477C, T414C, T195C, T146C) have been found in the brains of 
patients with Alzheimer’s disease compared to controls [136]. Taken with the recent findings of 
increased mutations in both T16519C and T195C in those with other psychiatric diseases [133], 
it may be plausible to hypothesize that like nuclear DNA, certain blocks of mtDNA are 
consistently inherited and evolutionarily conserved. While T16519C may not itself alter 
mitochondrial function, it may be consistently associated with other regions within the D-loop 
that are involved in the replication of the genome itself or are involved with the production of 
transcription products necessary to build the respiratory complex proteins. 
 
5.3 WEAKNESSES 
Due to the exploratory nature of this study, predetermined power and sample size 
calculations were not done to maximize the chance of finding an association between the 
mtDNA variants and PTS and overall this study was under powered. All possible mitochondrial 
polymorphisms were selected in the original sample of 136 patients via the MitoChip V2 assay; 
however, there were several with very little variation in regard to outcomes of EPTS and LPTS 
which made any further analysis impossible. In order to maximize sample size, additional 
analyses were conducted of the variants vs. all PTS, however, the slight associations shown here 
for EPTS and LPTS were not apparent. Additionally, McRae et al. have done power analysis of 
whole mitochondrial genome association studies and they have estimated that approximately 900 
cases and controls would be needed to detect an allele with a relative risk of 3 at a power of 80%.  
They further estimated that number would rise to 3000 to detect a relative risk of 2.0 and 10,000 
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to detect a relative risk of 1.5.  They do note, however, that sample sizes of 1000-10,000 are not 
uncommon in genome wide association studies of nuclear SNPs, and that adding in 
mitochondrial genotyping with tools such as the MitoChip V2 assay would only trivially increase 
the overall cost of the study [137]. 
 Also, due to the retrospective nature of this study, PTS information was abstracted from 
medical charts rather than from direct monitoring or patient interviews and could have led to an 
underestimation of the true seizure risk.  Additionally, time to first seizure was the primary 
measure of PTS so there was no ability to assess recurrent seizure risks [20]. In many studies of 
mitochondrial polymorphisms, race is typically removed as certain haplogroups are known to 
have much higher proportions of certain mutations due to their ancestral lineage. In the initial 
stages of this study analyses of all injury, clinical and mtDNA variants to PTS categories were 
done limited only to Caucasians and with all races left in. There were no differences found 
between any of the potential associations presented here between those analyses. In total there 
were 15 subjects (13 No PTS, 2 PTS) who did not self-identify as Caucasian. The ultimate 
decision to leave these subjects in was based upon the limited sample size and the results of my 
initial analyses. 
5.4 STRENGTHS 
While no significant independent associations were found between the 19 mitochondrial 
variants and the outcome of PTS, some of the findings from this study may help guide future 
research in this area.  This study was able to provide some limited evidence that mitochondrial 
polymorphisms may in fact play a role in unraveling the complex phenotype that is PTS. 
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5.5 CONCLUSION  
 From the outset of this dissertation project, my interest in PTS has been in the 
heterogeneous nature of the condition.  While we know that those with the most severe injuries 
are most likely to develop PTS, and that certain injuries (particularly penetrating head injuries) 
are more likely to cause seizures, we still lack reliable means of determining who will go on to 
develop PTS or intractable lifelong epilepsy (PTE).  I’ve also come to think (although I’m 
certainly not the first one to do so) that EPTS and LPTS may represent different biological 
pathways with their own unique environmental and genetic markers.  Over the course of this 
research I have poured over the literature regarding PTS and PTE and one theme that continues 
to emerge is a lack of reliable biomarkers that could help provide clues as to who might develop 
PTS/PTE. While at first I had hoped to find the “smoking gun” in the mitochondrial genome in 
the form of a functional polymorphism, what I’ve learned is that there are possible clues hidden 
in areas that are most often overlooked (the D-loop).  Perhaps the answer to a reliable biomarker 
lies buried in that short sequence of base pairs.  A study that looks at the mtDNA profile of those 
with TBI compared to healthy controls may reveal fundamental differences between their 
mitochondrial genomes. 
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APPENDIX A: Mitochondrial Diseases with Seizure Phenotypes: tRNA/rRNA Mutations 
Condition Population Gene  Mutation  
Location 
References 
MERRF/ 
KSS 
42yo Caucasian male tRNA Leucine G3255A Nishigaki, 2003, [138]  
MELAS Family study, n=4 tRNA Leucine A3243G Enter, 1991, [139] 
 
MELAS Case Report tRNA Leucine G3244A Kirino, 2005, [140] 
MELAS Japanese MELAS patients, n=94 tRNA Leucine A3252G Goto, 1995, [141] 
MELAS 45yo male Caucasian tRNA Leucine C3256T Morares, 1993, [142] 
MELAS 166 MELAS patients screened,  
n=5 with this mutation 
tRNA Leucine T3258C Sternberg, 2001, [143] 
MELAS N=3 of 41 MELAS patients tRNA Leucine T3271C Goto, 1991, [144] 
MELAS N=1 of 46 MELAS patients tRNA Leucine T3291C Goto, 1994, [145] 
MELAS/ 
MERRF 
N=1, patient also had 3243 mutation tRNA Leucine A12308G Pulkes, 2000, [146] 
MERRF Family study (n=3) tRNA Lysine  A8344G Shoffner, 1990, [24] 
Noer, 1991, [147] 
MERRF n=5 tRNA Lysine  T8356C Silvestri, 1992, [148] 
MERRF Two Japanese families tRNA Lysine G8363A Ozawa, 1997,[149] 
MERRF 7yo Austrian boy tRNA Lysine G8361A Rossmanith, 2003, [150] 
CPEO/ 
MYO 
39yo female  tRNA Lysine G8342A Tiranti, 1998, [151] 
MINGIE 7yo male developed seizures tRNA Lysine G8313A Verma, 1997, [152] 
 
PEM 33yo female tRNA Glycine T10010C Bidooki, 1997, [153] 
GER/SIDS/ 
ENC 
N=8, siblings  tRNA Glycine A10044G Santorelli,1996, [154] 
ENC 7mo, female, generalized seizures tRNA Isoleucine C4320T Santorelli, 1995, [155] 
Familial ENC N=3, mother and 2 sons tRNA Isoleucine G4284A Corona, 2002, [156] 
MERRF 42yo Italian female tRNA Phenylalanine G611A Mancuso, 2004, [157] 
MELAS 1 of 5 MELAS patients tRNA Phenylalanine G583A Hanna, 1998, [158] 
ENC/Ataxia n=1 tRNA Valine G1606A Tiranti, 1998, [151] 
MELAS 1 of 22 MELAS patients tRNA Valine G1642A De Coo, 1998, [159] 
ENC/MYO 11yo female tRNA Asparagine A7543G Shtilbans, 1999, [160] 
ENC 5yo female, family hx of seizures. tRNA Cysteine T5814C Manfredi, 1996, [161] 
MELAS n=1 tRNA Glutamine G4332A Bataillard, 2000, [162] 
MERRF/ 
MELAS 
26yo Italian male tRNA Histidine G12147A Melone, 2004, [163] 
MERRF/ 
MELAS 
N=3, Japanese Family members tRNA Serine T7512C Nakamura 1995, [164] 
Jaksch, 1998, [165] 
ENC 16yo male tRNA Threonine G15915A Seki, 1997, [166] 
MELAS 35yo female, also had A3243G 16S – RNA C3093G Hsieh, 2004, [167] 
RETT/ENC N=15 Chinese children with RETT 16S – RNA C2835T Tang, 1997, [168] 
 
CPEO, Chronic Progressive External Ophthalmoplegia; ENC, Encephalopathy; GER/SIDS, GastroEsophageal Reflux/Sudden Infant Death 
Sydrome; KSS, Kearns-Sayre Syndrome; MELAS, Mitochondrial Encephalopathy with Lactic Acidosis and Stroke-like episodes; MERRF, 
Myoclonus Epilepsy with Ragged Red Fibers; MINGIE, Myo-Neuro GastroIntestinal Encephalopathy; MYO, Myoclonus; PEM, Progressive 
Myoclonic Epilepsy; RETT Syndrome 
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APPENDIX B: Mitochondrial Diseases with Seizure Phenotypes: Coding Region Mutations 
Condition Population Complex / Gene Mutation  
Location 
References  
MELAS/ 
BSN 
22yo Spanish female Complex I / ND1 T3308C Campos, 1997, [169] 
MELAS/ 
LHON 
43yo female Complex I / ND1 G3376A Blakely, 2005, [170] 
MELAS Pt. 1 – 7yo Caucasian male 
Pt. 2 – 14yo Caucasian female 
Pt. 3 -  14yo Chinese male 
Complex I / ND1 
Complex I / ND1 
Complex I / ND1 
G3697A 
G3946A 
T3949C 
Kirby, 2004, [171] 
LS 42yo male Complex I / ND3 T10191C Taylor, 2001, [172] 
LS 67yo male Complex I / ND4 C11777A Deschauer, 2003, 
[173] 
MELAS 19yo Caucasian female Complex I / ND4 A11084G Lertrit, 1992, [174] 
MELAS/ 
LHON 
Pt. 1 – 8.5yo male 
Pt. 2 – 9yo male 
Complex I / ND5 
Complex I / ND5 
A12770G 
A13045C 
Liolitsa, 2003, [175] 
LS/MELAS 16yo Italian male Complex I / ND5 A13084T Crimi, 2003, [176] 
MELAS 43yo male Complex I / ND5 G13513A Santorelli, 1997, 
[177] 
MELAS/ 
ENC 
1 male and 1 female, Italian Complex I / ND5 A13514G Corona, 2000, [178] 
LS N=3, 2 brothers and 1 unrelated female Complex I / ND6 G14459A Kirby, 2000, [179] 
MELAS 7yo female, Danish Complex I / ND6 G14453A Ravn, 2000, [180] 
MULTI 19yo female Complex III / cyt b A15579G Wibrand, 2001, 
(157) 
EXIT/ENC 34yo female Complex III / cyt b G15242A Keightley, 2000, 
[181] 
HCM N=5 with mutation, 1 female with seizures Complex III / cyt b G15243A Valnot, 1999, [182] 
ENC / EPI 17yo female, German Complex IV / COX I C6489C Varlamov, 2002, 
[183] 
ENC / 
MULTI 
21yo female Complex IV / COX I G6930A Bruno, 1999, [184] 
MELAS/ 
ENC 
11yo male Complex IV / COX III G9952A Manfredi, 1995, 
[185] 
LS 5yo Complex V / A6 T8993C Santorelli, 1994, 
[186] 
LS/NARP N=4, Family members  
all shared same mutation 
Complex V / A6 T8993G Harding, 1992, [187] 
 
BSN-Bilateral Striatal Necrosis; CPEO-Chronic Progressive External Ophthalmoplegia; ENC-Encephalopathy; EXIT-Exercise Intolerance; 
GER/SIDS-GastroEsophageal Reflux/Sudden Infant Death Sydrome; HCM-Hypertrophic Cardiomyopathy KSS-Kearns-Sayre Syndrome; 
LHON-Leiber’s Hereditary Optic Neuropathy; LS-Leigh Syndrome; MELAS-Mitochondrial Encephalopathy with Lactic Acidosis and Stroke-
like episodes; MERRF-Myoclonus Epilepsy with Ragged Red Fibers; MINGIE-Myo-Neuro Gastro GastroIntestinal Encephalopathy; MYO-
Myoclonus; MULTI-Multisystem Disease; NARP- Neurogenic muscle weakness Ataxia and Retinitis Pigmentosa; PEM-Progressive Myoclonic 
Epilepsy; RETT Syndrome 
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APPENDIX C: Aim 1 Additional Tables 
Table C 1: mtDNA Variants vs. All PTS 
 
mtDNA  
Variant  
No PTS + 
Count (%) 
PTS+ 
Count (%) 
p-value* 
(n) 
T146C 
T 
C 
 
56 (71.8) 
  6 (75.0) 
 
22 (28.2) 
  2 (25.0) 
 
p=1.000 
(86) 
T195C ¢ 
T 
C 
 
122 (75.8) 
  29 (69.0)  
 
39 (24.2) 
13 (31.0) 
 
p=0.428 
(203) 
T477C ¢ 
T 
C 
 
129 (75.9) 
    6 (60.0) 
 
41 (24.1) 
  4 (40.00) 
 
p=0.260 
(180) 
C3494T 
C 
T 
 
62 (72.1) 
0 (0.0) 
 
24 (27.9) 
0 (0.0) 
 
--- 
(86) 
T4126C¢ 
T 
C 
 
121 (75.6) 
  39 (76.5) 
 
39 (24.4) 
12 (23.5) 
 
p=0.902 
(211) 
A4917G¢ 
A 
G 
 
146 (76.4) 
  14 (66.7) 
 
45 (23.6) 
  7 (33.3) 
 
p=0.323 
(212) 
C7028T 
C 
T 
 
21 (70.0) 
41 (73.2) 
 
  9 (30.0) 
15 (26.8) 
 
P=0.751 
(86) 
A8701G 
A 
G 
 
55 (72.4) 
  7 (70.0) 
 
21 (27.6) 
  3 (30.0) 
 
P=1.000 
(86) 
A10398G¢ 
A 
G 
 
110 (76.4) 
  34 (69.4) 
 
34 (23.6) 
15 (30.6) 
 
p=0.331 
(193) 
A10550G 
A 
G 
 
57 (74.0) 
  5 (55.6) 
 
20 (26.0) 
  4 (44.4) 
 
P=0.434 
(86) 
T10873C 
T 
C 
 
58 (71.6) 
  4 (80.0) 
 
23 (28.4) 
  1 (20.0) 
 
P=1.000 
(86) 
A11947G 
A 
G 
 
59 (71.1) 
   3 (100.0) 
 
24 (28.9) 
  0 (0.0) 
 
p=0.557 
(86) 
A12308G 
A 
G 
 
45 (72.6) 
17 (70.8) 
 
17 (27.4) 
  7 (29.2) 
 
p=0.871 
(86) 
C12705T 
C 
T 
 
53 (71.6) 
  9 (75.0) 
 
21 (28.4) 
  2 (25.0) 
 
p=1.000 
(86) 
G13708A 
G 
A 
 
57 (74.0) 
  4 (57.1) 
 
20 (26.0)    
  3 (42.9) 
 
p=0.386 
(86) 
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¢ - mtDNA variants with additional samples 
* - Chi-squared analysis and Fisher’s Exact 
+ - Deaths with no evidence of seizure removed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mtDNA  
Variant  
No PTS + 
Count (%) 
PTS+ 
Count (%) 
p-value* 
(n) 
A14233G 
A 
G 
 
58 (72.5) 
  4 (66.7) 
 
22 (27.5) 
  2 (33.3) 
 
p=1.000 
(86) 
C14766T 
C 
T  
 
24 (72.7) 
38 (73.1) 
 
  9 (27.3) 
14 (26.9) 
 
p=0.972 
(85) 
T16519C¢ 
T 
C 
 
 77  (71.3) 
 51 (81.0) 
 
31 (28.7) 
12 (19.0) 
 
p=0.160 
(171) 
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APPENDIX D: Aim 2 Additional Tables 
Table D 1 – Comparison of Variants to SDH and Cranial Surgery in LPTS 
mtDNA Variant 
(n) 
NO SDH 
Count (%) 
SDH 
Count (%) 
p-value  NO Cranial Surgery 
Count (%) 
Cranial Surgery 
Count (%) 
p-value 
 
T146C (79) 
T 
C 
 
31 (43.7) 
  4 (50.0) 
 
40 (56.3) 
4 (50.0) 
 
1.000 
  
41 (61.2) 
4 (66.7) 
 
26 (38.8) 
2 (33.3) 
 
1.000 
T195C (165) 
T 
C  
 
52 (40.0) 
18 (51.4) 
 
78 (60.0) 
17 (48.6) 
 
0.225 
  
89 (61.4) 
19 (55.9) 
 
56 (38.6) 
15 (44.1) 
 
0.555 
T477C (167) 
T 
C 
 
69 (43.7) 
2 (22.2) 
 
89 (56.3) 
7 (77.8) 
 
0.304 
  
91 (62.3) 
5 (55.6) 
 
55 (37.7) 
4 (44.4) 
 
0.732 
C3494T (79) 
C 
T 
 
35 (44.3) 
0 (0) 
 
44 (55.7) 
0 
 
--- 
  
45 (61.6) 
0 (0.0) 
 
28 (38.4) 
0 (0.0) 
 
--- 
T4216C (171) 
T 
C 
 
54 (40.9) 
19 (48.7) 
 
78 (59.1) 
20 (51.3) 
 
0.462 
  
85 (59.9) 
26 (57.8) 
 
57 (40.1) 
19 (42.2) 
 
0.804 
A4917G (172) 
A 
G 
 
65 (41.9) 
8 (47.1) 
 
90 (58.1) 
9 (52.9) 
 
0.685 
  
98 (58.3) 
13 (68.4) 
 
70 (41.7) 
6 (40.6) 
 
0.396 
C7028T (79) 
C 
T 
 
14 (50.0) 
21 (41.2) 
 
14 (50.0) 
30 (58.8) 
 
0.450 
  
17 (60.7) 
28 (62.2) 
 
11 (39.3) 
17 (37.8) 
 
0.897 
A8701G (79) 
A 
G 
 
30 (42.3) 
5 (62.5) 
 
41 (57.7) 
3 (6.8) 
 
0.455 
  
42 (60.9) 
3 (75.0) 
 
27 (39.1) 
1 (25.0) 
 
0.656 
A10398G (165) 
A 
G 
 
53 (41.7) 
18 (47.4) 
 
74 (58.3) 
20 (21.3) 
 
0.538 
  
82 (60.7) 
19 (54.3) 
 
53 (39.3) 
16 (45.7) 
 
0.488 
A10550G (79) 
A 
G 
 
33 (45.8) 
2 (28.6) 
 
39 (54.2) 
5 (71.4) 
 
0.454 
  
42 (62.7) 
 3( 50.0) 
 
25 (37.3) 
 3 (50.) 
 
0.669 
T10873C (79) 
T 
C 
 
33 (44.0) 
2 (50.0) 
 
42 (56.0) 
2 (50.0) 
 
1.000 
  
45 (61.6) 
0 (0.0) 
 
28 (38.4) 
0 (0.0) 
 
--- 
A11947G (79) 
A 
G 
 
34 (44.7) 
1 (33.3) 
 
42 (55.3) 
2 (66.7) 
 
1.000 
  
43 (61.4) 
 2 (66.7) 
 
27 (38.6) 
  1 (33.3) 
 
1.000 
A12308G (79) 
A 
G 
 
27 (46.6) 
8 (38.1) 
 
31 (53.4) 
13 (61.9) 
 
0.504 
  
33 (61.1) 
12 (63.2) 
 
21 (38.9) 
7 (36.8) 
 
0.875 
C12705T (79) 
C 
T 
 
30 (44.1) 
5 (45.5) 
 
38 (55.9) 
6 (54.4) 
 
1.000 
  
40 (60.6) 
5 (71.4) 
 
26 (39.4) 
2 (28.6) 
 
0.700 
G13708A (79) 
G 
A 
29 (41.4) 
5 (71.4) 
41 (58.6) 
2 (28.6) 
 
0.230 
  
40 (61.5) 
5 (71.4) 
 
25 (38.5) 
2 (28.6) 
 
0.704 
 
        
 113 
mtDNA Variant 
(n) 
NO SDH 
Count (%) 
SDH 
Count (%) 
p-value  NO Cranial Surgery 
Count (%) 
Cranial Surgery 
Count (%) 
p-value 
 
T13789C (79) 
T 
C 
32 (42.1) 
2 (100.0) 
44 (57.9) 
0 (0.0) 
0.187 43 (61.4) 
  2 (100.0) 
27 (38. 6) 
0 (0.0) 
0.525 
A14233G (79) 
A 
G 
 
33 (44.6) 
2 (40.) 
 
41 (55.4) 
3 (60.) 
 
1.000 
  
42 (61.8) 
  3 (60.0) 
 
26 (38.2) 
  2 (40.0) 
 
1.000 
C14766T (79) 
C 
T 
 
15 (48.4) 
19 (40.4) 
 
16 (51.6) 
28 (59.6) 
 
0.488 
  
18 (58.1) 
27 (65.9) 
 
13 (41.9) 
14 (34.1) 
 
0.333 
T16519C (160) 
T 
C 
 
44 (43.1) 
26 (44.8) 
 
58 (56.9) 
32 (55.2) 
 
0.836 
  
57 (58.8) 
35 (66.0) 
 
40 (41.2) 
18 (34.0) 
 
0.382 
 * Chi-square test of independence, or Fisher’s exact test 
--- Cells with 0 counts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 114 
 
Table D 2 – Initial Stratification of SDH by Variant by LPTS 
Variants (n)+ OR (95% CI) p- value*  
T146C (79) T – 1.210 (.379-3.857) 
C -  --- 
 
0.399 
T195C (165) T – 2.64 (.981-7.122) 
C – 11.90 (1.27-111.35) 
 
0.004 
T477C (167) T – 3.66 (1.39-9.58) 
C - .400 (.01-10.01) 
 
0.009 
 
C3494T (79) C – 1.61 (.529-4.90) 
T -  --- 
 
0.399 
T4216C (171) T – 7.56 (2.14-26.63) 
C - .662 (.127 – 3.45) 
 
0.004 
 
A4917G (172) A – 4.87 (1.75-13.51) 
G - .375 (.027-5.16) 
 
0.004 
 
C7028T (79) C – 3.33 (.522-21.27) 
T – 1.06 (.260-4.35) 
 
0.399 
A8701G (79) A – 1.83 (.562-5.98) 
G -  --- 
 
0.399 
 
A10398G (165) A – 3.80 (1.33-10.87) 
G – 3.42 (.594-19.80) 
 
0.003 
A10550G (79) A – 1.35 (.425-4.29) 
G - --- 
 
0.399 
T10873C (79) T – 1.59 (.521-4.89) 
C -  --- 
 
0.399 
A11947G (79) A – 1.65 (.541-5.06) 
G – 1.61 (.529-4.90) 
 
0.399 
A12308G (79) A – 1.02 (.296-3.52) 
G - --- 
 
0.399 
C12705T (79) C – 1.78 (.537-5.93) 
T - .800 (.037-17.19) 
 
0.399 
G13708A (77) G – 1.75 (.484-6.37) 
A – 1.50 (.055-40.63) 
 
0.547 
T13789C (78) T – 1.44(.471-4.42) 
C - --- 
 
0.435 
A14233G (79) A – 2.05 (.634-6.65) 
G - --- 
 
0.399 
C14766T (78) C – 2.95 (.476-18.34) 
T – 1.45 (.316-6.70) 
0.264 
T16519C (160) T – 4.10 (1.39-12.05) 
C – 1.71 (.288-10.19) 
0.008 
+ - Note the differing n’s for the 6 variants from the larger subset of samples. 
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Tables D 3-8 - Stratification of SDH by Variant by LPTS 
 
Table 3 - T195C 
T195C  
(n=165) 
 LPTS No LPTS OR (95% CI) p-value 
T SDH 
obs 
exp 
 
20 
15.6 
 
58 
62.4 
 
2.64(.981-7.12) 
 
0.049 
 No SDH 
obs 
exp 
 
6 
10.4 
 
46 
41.6 
  
 
      
C SDH 
obs 
exp 
 
7 
3.9 
 
10 
13.1 
 
11.90(1.27-111.35) 
 
0.018 
 No SDH 
obs 
exp 
 
1 
4.1 
 
17 
13.9 
  
 
Table D 4 - T477C 
T477C  
(n=165) 
 LPTS No LPTS OR (95% CI) p-value 
T SDH 
obs 
exp 
 
23 
16.3 
 
66 
72.7 
 
3.66(1.39-9.58) 
 
0.006 
 No SDH 
obs 
exp 
 
6 
12.7 
 
63 
56.3 
  
 
      
C SDH 
obs 
exp 
 
2 
2.3 
 
5 
4.7 
 
0.400(.016-10.01) 
 
1.000 
 No SDH 
obs 
exp 
 
1 
.7 
 
1 
1.3 
  
 
Table D 5 – T4216C 
T4216C  
(n=171) 
 LPTS No LPTS OR (95% CI) p-value 
T SDH 
obs 
exp 
 
24 
16.0 
 
54 
62.0 
 
7.56(2.14-26.63) 
 
0.000 
 No SDH 
obs 
exp 
 
3 
11.0 
 
51 
43.0 
  
 
      
C SDH 
obs 
exp 
 
3 
3.6 
 
17 
16.4 
 
0.662(.127-3.45) 
 
0.695 
 No SDH 
obs 
exp 
 
4 
3.4 
 
15 
15.6 
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Table D 6 – A4917G 
A4917G  
(n=172) 
 LPTS No LPTS OR (95% CI) p-value 
A SDH 
obs 
exp 
 
26 
18.0 
 
64 
72.0 
 
4.87(1.76-13.52) 
 
0.001 
 No SDH 
obs 
exp 
 
5 
13.0 
 
60 
52.0 
  
 
      
G SDH 
obs 
exp 
 
1 
1.6 
 
8 
7.4 
 
0.375(.027-5.17) 
 
0.576 
 No SDH 
obs 
exp 
 
2 
1.4 
 
6 
6.6 
  
 
Table D 7 – A10398G 
A10398G  
(n=165) 
 LPTS No LPTS OR (95% CI) p-value 
A SDH 
obs 
exp 
 
21 
15.1 
 
53 
58.9 
 
3.80(1.33-10.88) 
 
0.009 
 No SDH 
obs 
exp 
 
5 
10.9 
 
48 
42.1 
  
 
      
G SDH 
obs 
exp 
 
6 
4.2 
 
14 
15.8 
 
3.42(.594-19.80) 
 
0.238 
 No SDH 
obs 
exp 
 
2 
3.8 
 
16 
14.2 
  
 
Table D 8 – T16519C 
T16519C  
(n=165) 
 LPTS NO LPTS OR (95% CI) p-value 
T SDH 
obs 
exp 
 
20 
14.2 
 
38 
43.8 
 
4.10(1.39-12.05) 
 
0.007 
 No SDH 
obs 
exp 
 
5 
10.8 
 
39 
33.2 
  
 
      
C SDH 
obs 
exp 
 
4 
3.3 
 
28 
28.7 
 
1.71(.288-10.19) 
 
0.681 
 No SDH 
obs 
exp 
 
2 
2.7 
 
24 
23.3 
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Table D 9 – Initial Stratification of Cranial Surgery by Variant by LPTS 
Variant (n)+ OR (95% CI) p-value* 
T146C (73) T – 10.85 (2.66-44.28) 
C -  3.00 (.084-107.44) 
0.000$ 
T195C (179) T – 4.38 (1.86-10.32) 
C – 9.71 (1.63-57.72) 
0.000 
 
T477C (155) T – 3.83 (1.65-8.89) 
C -  --- 
--- 
 
C3494T (73) C – 8.88 (2.50-31.54) 
T -  --- 
--- 
 
T4216C (187) T – 4.37 (1.86-10.25) 
C – 7.00 (1.25-38.99) 
0.000 
 
A4917G (187) A – 4.12 (1.85-9.16) 
G – 24.00(1.68-340.99) 
0.000 
 
C7028T (73) C – --- 
T – 3.27 (.766-13.98) 
--- 
A8701G (73) A –  7.60  (2.11-27.32) 
G -  --- 
--- 
 
A10398G (170) A – 6.07 (2.43-15.13) 
G – 1.70 (.370-7.85) 
0.000 
 
A10550G (73) A – 12.00(2.92-49.26) 
G – 1.00  (.034-29.80) 
0.000$ 
T10873C (73) T – 8.88 (2.50-31.54 
C -  --- 
--- 
 
A11947G (73) A – 9.05 (2.52-32.44) 
G – --- 
--- 
A12308G (73) A – 17.05 (3.22-90.27) 
G – 2.00 (.214-18.68) 
0.000$ 
C12705T (73) C – 10.57 (2.58-43.15) 
T –   4.00 (.117-136.95) 
0.000$ 
G13708A (72) G – 8.22 (1.98-34.11) 
A – --- 
--- 
T13789C (72) T – 9.05 (2.52-32.44) 
C - --- 
--- 
A14233G (73) A – 8.14 (2,24-29.48) 
G - --- 
--- 
C14766T (72) C – --- 
T – 3.19 (.696-14.66) 
--- 
T16519C (150) T – 5.84 (2.13-15.99) 
C – 3.04 (.601-15.45) 
0.000 
 
+ - Note the differing n’s for the 6 variants from the larger subset of samples. 
* Chi-square test of independence or Fisher’s Exact test where appropriate. (bold: p<.05) 
$ - Not enough cases with risk allele and Cranial Surgery to evaluate, odds ratio and confidence intervals become unstable. 
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Tables D 10-14 - Stratification of Cranial Surgery by Variant by LPTS 
 
Table 10 - T195C 
T195C  
(n=179) 
 LPTS No LPTS OR (95% CI) p-value 
T Surgery 
obs 
exp 
 
20 
11.6 
 
36 
44.4 
 
4.39(1.86-10.32) 
 
0.000 
 No Surgery 
obs 
exp 
 
10 
18.4 
 
79 
70.6 
  
 
      
C Surgery 
obs 
exp 
 
8 
4.4 
 
7 
10.6 
 
9.71(1.64-57.72) 
 
0.010 
 No Surgery 
obs 
exp 
 
2 
5.6 
 
17 
13.4 
  
 
Table D 11 – T4216C 
T4216C  
(n=187) 
 LPTS No LPTS OR (95% CI) p-value 
T Surgery 
obs 
exp 
 
21 
12.4 
 
36 
44.6 
 
4.38(1.86-10.25) 
 
0.000 
 No Surgery 
obs 
exp 
 
10 
18.6 
 
75 
66.4 
  
 
      
C Surgery 
obs 
exp 
 
7 
3.8 
 
12 
15.2 
 
7.00(1.26-38.99) 
 
0.024 
 No Surgery 
obs 
exp 
 
2 
5.2 
 
24 
20.8 
  
 
Table D 12 – A4917G 
A4917G  
(n=187) 
 LPTS No LPTS OR (95% CI) p-value 
A Surgery 
obs 
exp 
 
24 
14.6 
 
46 
55.4 
 
4.13(1.86-9.17) 
 
0.000 
 No Surgery 
obs 
exp 
 
11 
20.4 
 
87 
77.6 
  
 
      
G Surgery 
obs 
exp 
 
4 
1.6 
 
2 
4.4 
 
24.0(1.69-340.99) 
 
0.017 
 No Surgery 
obs 
exp 
 
1 
3.4 
 
12 
9.6 
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Table D 13 – A10398G 
A10398G  
(n=170) 
 LPTS No LPTS OR (95% CI) p-value 
A Surgery 
obs 
exp 
 
21 
11.4 
 
32 
41.6 
 
6.07(2.43-15.14) 
 
0.000 
 No Surgery 
obs 
exp 
 
8 
17.6 
 
74 
64.4 
  
 
      
G Surgery 
obs 
exp 
 
5 
4.1 
 
11 
11.9 
 
1.71(.370-7.85) 
 
0.700 
 No Surgery 
obs 
exp 
 
4 
4.9 
 
15 
14.1 
  
 
Table D 14 – T16519C 
T16519C 
(n=150) 
 LPTS No LPTS OR (95% CI) p-value 
T Surgery 
obs 
exp 
 
18 
10.3 
 
22 
29.7 
 
5.84(2.14-15.99) 
 
0.000 
 No Surgery 
obs 
exp 
 
7 
14.7 
 
50 
42.3 
  
 
      
C Surgery 
obs 
exp 
 
4 
2.4 
 
14 
15.6 
 
3.05(.601-15.45) 
 
0. 211 
 No Surgery 
obs 
exp 
 
3 
4.6 
 
32 
30.4 
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APPENDIX E: Aim 3 Additional Tables 
Tables E 15-19- Stratification of LPTS by GOS at 6 months by Variant 
 
Table E 15 – T195C 
T195C 
(n=172) 
 LPTS No LPTS OR (95% CI) p-value 
T GOS 2-3 
obs 
exp 
 
12 
7.6 
 
58 
62.4 
 
4.48(1.21-16.68) 
 
0.016 
 GOS 4-5 
obs 
exp 
 
3 
7.4 
 
65 
60.6 
  
 
      
C GOS 2-3 
obs 
exp 
 
2 
1.8 
 
13 
13.2 
 
1.31(0.16-10.56) 
 
1.000 
 GOS 4-5 
obs 
exp 
 
2 
2.2 
 
17 
16.8 
  
 
Table E 16 – T4216C 
T4216C 
(n=179) 
 LPTS No LPTS OR (95% CI) p-value 
T GOS 2-3 
obs 
exp 
 
10 
6.7 
 
61 
64.3 
 
3.50(.92-13.32) 
 
0.053 
 GOS 4-5 
obs 
exp 
 
3 
6.3 
 
64 
60.7 
  
 
      
C GOS 2-3 
obs 
exp 
 
4 
2.9 
 
16 
17.1 
 
2.38(.38-14.70) 
 
0.410 
 GOS 4-5 
obs 
exp 
 
2 
3.1 
 
19 
17.9 
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Table E 17 – A4917G 
A4917G 
(n=180) 
 LPTS No LPTS OR (95% CI) p-value 
A GOS 2-3 
obs 
exp 
 
11 
7.7 
 
72 
75.3 
 
2.87(.87-9.41) 
 
0.072 
 GOS 4-5 
obs 
exp 
 
4 
7.3 
 
75 
71.7 
  
 
      
G GOS 2-3 
obs 
exp 
 
3 
1.8 
 
5 
6.2 
 
5.40(.44-66.67) 
 
0.275 
 GOS 4-5 
obs 
exp 
 
1 
2.2 
 
9 
7.8 
  
 
Table E 18 – A10398G 
A10398G 
(n=163) 
 LPTS No LPTS OR (95% CI) p-value 
A GOS 2-3 
obs 
exp 
 
10 
6.9 
 
52 
55.1 
 
2.89(.86-9.75) 
 
0.078 
 GOS 4-5 
obs 
exp 
 
4 
7.1 
 
60 
56.9 
  
 
      
G GOS 2-3 
obs 
exp 
 
4 
2.7 
 
16 
17.3 
 
4.00(.40-39.83) 
 
0.348 
 GOS 4-5 
obs 
exp 
 
1 
2.3 
 
16 
14.7 
  
 
Table E 19 – T16519C 
T16519C 
(n=142) 
 LPTS No LPTS OR (95% CI) p-value 
T GOS 2-3 
obs 
exp 
 
10 
6.1 
 
40 
43.9 
 
9.75(1.19-79.81) 
 
0.012 
 GOS 4-5 
obs 
exp 
 
1 
4.9 
 
39 
35.1 
  
 
      
C GOS 2-3 
obs 
exp 
 
1 
1.1 
 
18 
17.9 
 
.861(.073-10.18) 
 
1.000 
 GOS 4-5 
obs 
exp 
 
2 
1.9 
 
31 
31.1 
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